Author Index to Volumes 51–57

Abdelhay E, 56:171
Abe T, 54:77
Abeliovich D, 56:223
Abrahamson GM, 53:91
Abramov A, 56:223
Abramson A, 56:181
Abulaban M, 57:195
Adam LR, 52:37
Advani SH, 51:167
Aglietta M, 52:63; 55:235
Ajmar F, 52:43; 57:69
Alali K, 57:195
Alimena G, 51:73
Allen RG, 51:1
Al Zaman A, 57:195
Ambe K, 54:27
Andersen E, 53:35
André FS, 54:33; 56:177
Angervall L, 57:121
Angioni A, 55:261
Angrilli F, 51:223
Ansell SM, 51:273
Antonini P, 52:157
Antonopoulos M, 57:139
Antoun GR, 52:1
Aoki Y, 57:19
Ash RC, 55:39
Atkin NB, 52:113; 54:135; 55:153
Auerbach AD, 51:1
Auger MJ, 51:139
Austoni E, 52:181
Aventin A, 52:139

Bacchetti S, 54:39
Bachy-Delhomme M, 55:31
Bacigalupo A, 57:69
Badia L, 51:79; 52:173
Badiali M, 54:253
Baer MR, 57:153
Bailey D, 53:67
Bak M, 53:219
Baker MC, 52:113; 54:135
Balazs M, 55:243; 57:93
Balboni M, 57:47
Ball ED, 54:233
Balloni P, 55:261
Banavali S, 51:167
Banks RE, 51:103
Bardi G, 51:281; 55:11
Bartels H, 56:243
Bartelt DH Jr, 56:231
Bartnitzke S, 52:187; 53:283; 54:223; 56:277
Baruchel A, 54:239
Bastard C, 52:135
Bauchinger M, 55:49
Baumgartner M, 56:23
Beaumatin J, 53:23
Becher R, 52:71; 57:103
Békássy AN, 51:281
Belasco J, 54:119
Belge G, 56:277
Bell C, 54:153
Ben-Bassat I, 51:277
Benet I, 52:173
Beneyto M, 51:79; 52:173
Benitez J, 53:279
Benjes SM, 57:187
Ben-Neriah S, 56:223
Bennett RC, 53:205
Berger CS, 51:23; 52:165; 53:125; 54:273
Berger R, 51:57; 51:259; 52:157; 53:113; 54:197; 54:239
Berkman EM, 55:107
Berkowicz M, 51:277
Bernard P, 55:277
Bertheas MF, 55:31
Besses C, 54:133
Bester CJ, 51:273
Bettelheim P, 54:61
Beverstock GC, 57:225
Bhatia PS, 57:87
Bhavnani M, 55:257
Bianchi GP, 51:223
Bilhou-Nabera C, 55:277
Biörklund A, 55:125
Birnie GD, 56:57
Bixenman HA, 52:11
Bizet M, 52:135
Björk O, 55:97
Block AW, 51:207
Bogenmann E, 56:31
Boman B, 53:143
Boogaerts M, 55:217
Boop FA, 55:225; 57:181
Borrego D, 51:79
Børresen A-L, 57:31
Bosman F, 57:219
Bouabdallah K, 55:277
Bouzas LF, 56:171
Bowcock AM, 53:271
Bozola AR, 54:33; 56:177
Bradley MO, 53:57
Bradley T, 57:175
Bradt CI, 53:57
Bravard A, 56:23; 56:45
Breitbart EW, 53:265
Breuning MH, 57:225
Bridge JA, 51:35; 52:101; 54:173; 56:197; 57:87
Brito-Babapulle V, 55:1
Brizard A, 57:231
Brizard CP, 55:31
Brock P, 55:191; 57:137
Brøgger A, 57:31; 57:41
Brosens I, 51:279
Brothman AR, 55:79
Broustet A, 55:277
Brown RS, 51:121
Bruzzone R, 57:69
Buckle VJ, 53:91
Buist J, 53:15
Bullerdiek J, 52:187; 53:283; 54:223; 56:277
Bunin N, 54:119
Burgio VL, 51:73
Burke PJ, 54:11
Butler MG, 56:263
Butturini A, 52:19
Buys CHCM, 51:121; 52:207; 53:45

Caballín MR, 51:41; 54:133
Caillou B, 52:157
Calabrese G, 51:223
Caldeira LF, 54:33; 56:177
Callen DF, 51:255
Calmard P, 55:31
Cannizzaro LA, 55:139
Caporossi D, 54:39
Carli MG, 57:47
Carneiro F, 53:97

© 1991 Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

Cancer Genet Cytogenet 51:239–245 (1991)
0165-4608/91/$03.50

Carozzi F, 55:235
Carroll A, 55:249
Carstairs K, 53:67
Carter R, 53:67
Casati A, 51:89
Cascinelli N, 53:237
Cassiman JJ, 55:217
Castedo S, 53:97; 54:137; 54:183
Casteels-Van Daele M, 55:191; 57:137
Castilho WH, 54:33; 56:177
Castoldi G, 57:47
Catovsky D, 55:1
Cavalli-Sforza LL, 53:271
Cavazzini P, 57:47
Cedrone M, 51:73
Čepulić M, 55:231
Cerdá-Nicolás M, 57:235
Chadduck WM, 53:119; 54:55; 55:225; 57:181
Chen Z, 57:153
Chen-Lai J, 51:189; 54:21
Cherry LM, 53:281
Childs CC, 52:1
Chobotow M, 55:173; 56:7
Choi PHK, 54:91
Chott A, 54:61
Christensen BE, 53:35
Christodoulidou F, 54:229; 57:175
Coccia-Portugal MA, 51:273
Cogen PH, 53:271
Coleman M, 54:229
Coll MD, 54:133
Colp P, 54:101
Comelli A, 52:43
Comenzo R, 55:107
Conway T, 53:161
Cooper CS, 53:101
Cork A, 52:1
Correia C, 54:137
Cortez J, 54:247
Craft AW, 52:37
Craig JM, 55:157
Cremer T, 57:103
Creutzig U, 54:277
Crossen PE, 57:187
Crowson ML, 54:55
Cui MY, 56:31
Cuneo A, 57:47
Curtin JP, 54:143
Dabdoub R, 51:125
da Costa M, 57:175
Dadey B, 51:207
Dahl RJ, 56:231
Dahlenfors R, 55:19
Dal Cin P, 51:279; 54:223; 55:115; 55:191; 57:137
Dale BM, 56:255
Dalla-Favera R, 56:57
Daly HA, 57:233
Dam A, 53:15; 54:215
Daneshvar L, 53:271
Daniel M-T, 54:239
Darling J, 53:101
Datta T, 55:49
Dauwerse JG, 57:225
David L, 53:97; 54:137
Davies MF, 55:269
Davis BH, 54:233
Davis JR, 52:193
Davison EV, 52:37
De Bernardi B, 54:253
Debiec-Rychter M, 52:51
De Braekeleer M, 53:75
Decker H-JH, 51:23
Defferrari R, 52:43; 57:69
de Graaff WE, 57:59
de Gramont A, 51:85; 52:123
DeHarven E, 53:67
Dejana A, 57:69
de Jong B, 53:15; 54:183; 54:215; 57:59; 57:219
Delabie J, 53:229
de la Chica R-A, 55:133
del Ciotto N, 52:85
del Potro E, 54:163
de Oliveira MSP, 56:171
Derré J, 53:113
Dervenoulas J, 55:149
Desforges JF, 55:107
de Villiers E-M, 52:187
Dewald GW, 55:39
Dewar AE, 51:103
De Wever I, 55:115; 55:191; 57:137
de Wolfe-Peeters C, 53:229
Di Bartolomeo P, 51:223
Dictor M, 55:125
Di Girolamo G, 51:223
Diverio D, 51:73
Di Virgilio C, 51:223
Dmoszyńska A, 55:173
Dobrovic A, 56:255
Dofuku R, 55:207
Doi O, 57:19
Dominici C, 54:253
Donald JA, 51:45
Donner LR, 54:1
Donti E, 54:265; 56:57; 56:203
Donti GV, 56:203
Dracopoli NC, 54:109
Dreyfus B, 57:231
Drivsholm A, 53:35
Dubé ID, 51:189; 53:67; 54:21; 55:85
Duncan MH, 53:257
Dürst M, 52:187
Dutrillaux B, 52:27; 53:23; 56:23; 56:45

Egozcue J, 54:133
Ehlert U, 53:265
Elder FFB, 55:249
Emmerich B, 55:49
Erling MA, 51:35
Evans A, 54:139
Evensen SA, 57:41
Evers J, 57:219
Eyden B, 54:267

Faa G, 53:247
Fagioli F, 57:47
Falkson G, 51:273
Farber PA, 54:119
Farrants G, 57:31
Faustinella F, 54:83
Fayos JS, 53:279
Felix EA, 52:1
Feng X-L, 55:197
Fernandez LA, 54:101
Fernández-Rañada JM, 54:163
Ferro MT, 54:163
Ferti A, 57:139
Ferti-Passantonopoulou A, 51:183; 54:259; 55:149
Fidler IJ, 56:209
Fiebig HH, 51:23
Filatov LV, 56:11
Finley Austin MJ, 54:71
Fioretos T, 51:255
Fitzgerald PH, 55:129; 57:143
Flexor M-A, 51:259
Flodérus U-M, 55:11
Fodstad Ø, 57:31
Fonatsch C, 53:139; 56:243
Fontana V, 54:253
Ford HE, 56:255
Fosså SD, 57:41

Fossati GS, 52:85
Foucar K, 53:257
Fox MF, 55:153
Fraccaro M, 52:85
Franchi PG, 51:223
Frassoni F, 57:69
Freund M, 53:139; 56:243
Frost P, 54:153
Fugazza G, 52:43; 57:69

Gaiger A, 56:189
Gale RP, 52:19
Gama NB, 55:73
Gama R, 55:73
García-Sagredo JM, 54:163
Garipidou V, 52:107
Garner DL, 56:73
Garson OM, 53:205
Gasques JAL, 54:33; 56:177
Gatti RA, 56:143
Geddes AD, 52:201
Geisler C, 53:35
Geissler K, 54:61; 56:189
Geng J-S, 55:197
George D, 57:133
Gerbault-Seureau M, 52:27
Ghetti P, 51:89
Ghidoni A, 53:237
Ghione F, 55:261
Ghose T, 54:101
Gibson L, 54:129
Giorgi R, 51:89
Gledhill S, 51:103
Godio L, 52:63
Gollin SM, 57:169
Gong J, 51:215
Gonsebatt M-E, 54:247
Gonzalez-Canali G, 51:85; 52:123
Gopal R, 51:167
Gorman PA, 51:13
Grant CS, 56:231
Grassi C, 53:237
Green RE, 51:113
Grierson HL, 51:143
Griffin CA, 54:11; 55:181; 56:87
Grosveld G, 52:143
Grote W, 54:269
Groupe Français de Cytogénétique Hématologique, 55:57; 55:101
Gu J, 51:215
Guazzelli C, 55:261
Guerneri S, 52:181
Guerras L, 55:133
Guo Y, 51:215

Haas OA, 53:75; 54:61; 56:189
Haase D, 56:243
Hagemeijer A, 52:143; 54:61
Hägerstrand I, 51:281
Hainsworth PJ, 53:205
Hamers A, 57:219
Han T, 51:207
Hansen MM, 53:35
Harbott J, 54:277
Hardingham JE, 56:255
Harnett PR, 54:109
Harrison CJ, 55:257
Hasselbalch H, 53:35
Hawkins AL, 54:11
Hawkins JM, 52:79; 55:157
Hay ID, 56:231
Hayward NK, 54:109
Heath D, 56:157
Heaton DC, 57:187
Hecht BK, 52:131; 53:137; 54:245; 55:113; 57:229
Hecht F, 52:131; 53:137; 54:127; 54:245; 55:113; 57:229
Heim S, 51:255; 51:281; 55:11; 55:125, 56:39; 57:161
Heimdal K, 57:41
Henn T, 56:189
Herbert A, 55:35
Herrmann MA, 56:231
Herrmann ME, 57:209
Higashi K, 55:125
Higashiyama M, 57:19
Hill RB, 53:57
Hillion J, 51:259; 54:197
Himeno Y, 56:65
Hirscberg H, 57:41
Hoffschir F, 56:23
Hoo JJ, 51:239
Hopfer SM, 53:57
Horai T, 57:19
Hovig E, 57:31
Hsieh H-F, 55:67
Hsu TS, 53:281
Huang DP, 54:91
Hull YJ, 51:255
Huret JL, 57:231

Ichimaru M, 51:63; 51:67
Iino H, 54:27
Illeni MT, 53:237
Inazawa J, 54:77
Inoue K, 54:77
Iolascon A, 54:253
Iselius L, 55:97
Ishibashi Y, 56:163
Ishibe T, 56:65
Itoyama T, 51:67
Izutsu K, 51:155

Jacky PB, 53:105
Jacobs A, 56:1
Jacrot M, 55:265
Janardhana V, 51:113
Janatipour M, 54:205
Jarzabek V, 52:165
Jaubert J, 55:31
Jauch A, 57:103
Jenkins RB, 56:231; 56:263
Jensen IM, 57:79
Jensen KB, 53:35
Jin L, 55:67
Jin Y, 55:125
Johansson B, 51:281; 56:39
Johansson M, 57:121
Johnson CH, 53:83
Johnson PRE, 55:257
Jorgenson KF, 52:1
Joyce RA, 57:169

Kadam PR, 51:167
Karakousis CP, 51:195
Karnes PS, 56:31
Katsuta K, 51:155
Katz JA, 55:249
Kawasaki RS, 54:33; 56:177
Kazmierczak B, 54:223
Kearney L, 57:109
Kearsley JH, 54:109
Kefford RF, 51:45; 54:109
Kelly S, 53:91
Kerbel RS, 54:153
Kerim S, 52:63; 55:235
Khan SA, 54:139
Kiechle-Schwarz M, 51:23; 53:125; 54:273
Kindblom L-G, 57:121
Kishikawa H, 54:27
Kitagawa T, 55:207
Klock RJ, 51:189
Knees-Matzen S, 53:265
Knutsen T, 52:11
Kobayashi K, 56:163
Kodama A, 56:281

Kodama K, 57:19
Kodama S, 53:185
Kohno T, 51:63
Kojis TL, 56:143
Köller U, 54:61
Komatsu K, 53:185
Komatsu N, 57:53
Konja J, 54:67
Koops HS, 53:45; 57:59
Kotasek D, 56:255
Kovacs BW, 53:143
Kowalczyk JR, 55:173; 56:7
Krajewski A, 51:103
Krause JR, 57:169
Kraynak A, 53:57
Krishnamurthy M, 55:273
Kristoffersson U, 51:57; 56:39
Krsnik I, 54:163
Kruize YCM, 53:45
Krulik M, 51:85; 52:123
Kuffel DG, 55:39
Kuiken G, 53:45
Kullendorff C-M, 51:281

Labardini J, 54:247
Labraña X, 55:133
Ladaga LE, 55:79
Lampert F, 54:277
Lanfrancone L, 56:57
Lange B, 54:119
Langholm R, 57:41
Lanspa S, 53:143
Larizza L, 54:83
Larsen C-J, 51:259; 54:197
Las Heras G, 52:139
Laun L, 56:171
Lawce H, 52:11
Le Beau MM, 52:93
LeBrun DP, 54:21
Lecca U, 53:247
Lechner K, 54:61; 56:189
Le Coniat M, 53:113
Lee CLY, 54:101
Lee JCK, 54:91
Lee SHS, 54:101
Leeuw JA, 53:45
Lefrancois D, 56:45
Leizerowitz R, 56:223
Le Marc'hadour P, 55:265
Lemieux N, 53:23
Lemons RS, 53:83
Lenormand B, 52:135
Leong SPL, 51:195; 52:193
Lerer I, 56:223
Leroux D, 55:265
Lewin RJ, 51:35
Lewis MES, 55:85
Li FP, 51:121; 55:163; 55:167
Li H, 55:207
Li P, 55:197
Li Y-S, 52:93
Ligorsky R, 57:153
Lin B, 51:215
Lin CC, 51:239
Lin YJ, 56:181
Linares G, 52:157
Lindgren V, 54:129
Lion T, 56:189
Lisker R, 54:247
Liu J, 55:207
Liu Q-Z, 55:197
Liu Yin JA, 55:257
Llombart-Bosch A, 57:235
Lo K-W, 54:91
Lombardo C, 53:237
Longee DC, 57:181
Longo L, 54:265
Lopes C, 53:97
López-Ginés C, 57:235
Lothe R, 57:31
Louvet C, 51:85; 52:123
Lu D, 51:215
Lucas GS, 55:269
Luccioni C, 53:23; 56:45
Lund B, 53:35
Lundgren R, 51:57
Luthardt F, 57:133
Lynch HT, 53:143; 53:161
Lynch J, 53:143; 53:161

Maccari A, 56:203
MacDonald GR, 55:79
Macera MJ, 54:229; 57:175; 57:195; 51:139
Madsen AL, 53:219
Maeda T, 51:63
Magnani I, 54:83
Mahoney DH, 55:249
Majer RV, 55:35
Malcolm AJ, 52:37
Malfoy B, 52:27
Malm C, 56:39
Malone M, 51:13
Mamayeva SE, 56:11
Mamon Z, 51:277
Mandahl N, 51:255; 55:11; 55:125; 57:161
Mantovani F, 52:181
Maraschio P, 52:85
Mareni C, 57:69
Marit G, 55:277
Mark J, 55:19
Marosi C, 54:61
Martin PK, 52:11
Massaad L, 53:23
Matilla A, 55:133
Mayall BH, 55:243; 57:93
McCarthy WH, 51:45
McConnell TS, 53:257
McKeithan T, 53:67
McNeal JE, 55:79
McNutt MA, 57:133
Mecucci C, 51:73; 53:229; 55:217; 55:261
Medchill MT, 53:125; 54:273
Mehta AB, 55:157
Meloni A, 51:35; 51:137; 53:83; 53:199
Meng C-L, 55:67
Mertens F, 56:39
Metzger AK, 53:271
Miano C, 55:261
Michaux J-L, 53:229
Mick R, 52:93
Millá F, 52:139
Miller CB, 54:11
Miller DA, 56:263
Mills LE, 54:233
Milunsky A, 57:201
Mine M, 51:67
Misawa S, 54:77; 57:19
Mitelman F, 51:255; 55:11; 55:125; 56:39; 57:161
Miura Y, 57:53
Moerman P, 55:115
Mohamed A, 57:209
Møller P, 57:41
Monconduit M, 52:135
Morgan R, 51:35; 52:165; 53:83; 57:153
Mori Y, 57:19
Moriyama-Gonda N, 56:65
Morris CM, 57:143
Morrison MJ, 57:187
Moses HL, 56:263
Mostafavipour SH, 57:195
Motoyoshi K, 57:53
Mougeot-Martin M, 52:123
Mouron BJ, 57:87
Muleris M, 56:45
Murai M, 57:53

Murakami T, 56:281
Muroi K, 57:53
Mutchinick O, 54:247

Nacheva E, 55:135
Nair C, 51:167
Nakagawa H, 54:77
Nakamura H, 51:63; 51:67
Nakata K, 54:27
Nakazato H, 54:77
Nakić M, 54:67
Nanjangud GJ, 51:167
Nanni P, 54:83
Nashiro K, 56:163
Neff JR, 52:101; 54:173; 56:197; 57:87
Nemana L, 56:237
Neuman Y, 51:277
Ng AYT, 54:91
Nichols WW, 53:57
Nicoletti B, 54:39
Nicoletti G, 54:83
Nicotera TM, 53:1
Nielsen JB, 53:35
Nisen PD, 57:11
Nishi M, 54:77
Noël H, 53:229
Nomura K, 55:207
Nowell PC, 54:119
Nuzzo F, 51:89

Oda E, 54:27
Oda S, 54:27
Ohyashiki JH, 56:281
Ohyashiki K, 56:281
Oikawa S, 54:77
Okumura Y, 53:185
Oosterhuis JW, 53:15; 53:45; 54:183; 54:215; 57:59; 57:219
Oscier DG, 53:91
Osella P, 57:201
Osinga J, 53:45
Öst Å, 55:97
Otsuka F, 56:163

Padron F, 55:133
Palau F, 51:79; 52:173
Palka G, 51:223
Palou L, 54:133
Paltriccia R, 56:203
Panagiotopoulos G, 57:161
Panani AD, 51:183; 54:259; 55:149; 57:139
Pandis N, 51:281; 55:11; 57:161
Pappa V, 55:149
Parmentier C, 52:157
Parruti G, 51:223
Parshad R, 57:1
Pasquier B, 55:265
Patel AM, 55:79
Pathak S, 56:209
Pearce-Birge L, 54:247
Pearson ADJ, 52:37
Pedersen B, 57:79
Pedersen-Bjergaard J, 55:119
Pedron S, 53:125
Peehl DM, 55:79
Pelicci P-G, 54:265; 56:57
Pérez A, 51:41
Persons DL, 56:197
Peters GB, 56:255
Petersen SE, 53:219
Petković I, 54:67; 55:231
Petti MC, 51:73
Pfleiderer A, 54:273
Philip P, 53:35; 55:119
Photopulos G, 55:89
Piguet H, 52:135
Pinkel DP, 52:1
Pinkerton PH, 51:189; 54:21
Piva N, 57:47
Placucci M, 53:237
Plaja A, 55:133
Poldre PA, 54:21
Polliack A, 56:223
Pontes JE, 51:137
Poon A, 55:85
Popp S, 57:103
Prakash O, 51:125
Prentice HG, 55:157
Prescher G, 52:71
Price FM, 57:1
Prieto F, 51:79; 52:173
Prieur DJ, 53:105
Pritchard J, 51:13
Proesmans W, 57:137
Propert DN, 51:113
Provan A, 55:35
Pueyo JM, 55:133
Purtilo DT, 51:143

Qiu JY, 57:103
Qumsiyeh MB, 55:89

Rabinowitz R, 56:223
Rack K, 53:91
Rammeloo RHU, 54:183
Ramot B, 51:277
Rao UNM, 54:173
Raphael KL, 53:205
Rapoport BL, 51:273
Raptis S, 51:183; 54:259; 55:149; 57:139
Rechavi G, 51:277
Reeves BR, 53:101
Rege-Cambrin G, 52:63; 55:235
Reichle A, 55:49
Reiffers J, 55:277
Reimers U, 53:265
Reis MD, 51:189
Reiter A, 54:277
Resino M, 54:163
Reynaud J, 55:31
Ribeiro RC, 56:171
Ribera JM, 52:139
Ricoul M, 56:23
Rieder H, 53:139
Riehm H, 54:277
Ries CA, 53:83
Riske CB, 53:83
Ritter J, 54:277
Ritterbach J, 54:277
Rizzo MT, 56:203
Robinson JB, 51:189
Roloson GJ, 53:119; 54:55; 55:225; 57:181
Rommel B, 52:187; 54:223
Rosati D, 55:261
Roser M, 53:265
Rosner E, 51:277
Ross FM, 51:103; 51:139
Roth D, 55:107
Rous GP, 53:279
Rovini D, 53:237
Rowley JD, 52:93
Rüdiger HW, 53:265
Ruz L, 54:247
Rydholm A, 57:161

Sacchi N, 57:109
Sadamori N, 51:63; 51:67; 51:131
Sage RE, 56:255
Saglio G, 52:63; 55:235
Saikia T, 51:167
Saint-Ruf C, 52:27
Sakamoto S, 57:53
Sallerfors B, 56:39
Salmon J, 51:45
Salvidio E, 52:43
Samples DM, 51:125
Samuel IP, 51:239

Sandberg AA, 51:23; 51:35; 51:137; 51:195; 51:207; 52:101; 52:165; 52:193; 53:83; 53:125; 53:199; 54:115; 54:173; 54:273; 55:163; 55:167; 57:153
Sanford KK, 57:1
San-Román C, 54:163
Sansone R, 54:253
Santos G, 55:181
Sasagawa I, 51:67
Sasaki MS, 53:185
Sasi R, 51:239
Sato Y, 57:53
Sawyer JR, 53:119; 54:55; 55:225; 57:181
Sayed Aly M, 55:191
Scappaticci S, 52:85
Scaravaglio P, 52:63; 55:235
Schaison G, 54:239
Scheffer H, 53:45
Schellhammer PF, 55:79
Schellong G, 54:277
Schlegelberger B, 54:269
Schlumberger M, 52:157
Schneider NR, 57:11
Schraven KD, 54:247
Schultz CG, 55:39
Schwartz HS, 56:263
Scott JG, 53:67
Secker-Walker LM, 52:79; 52:107; 55:157
Sempere A, 51:79
Senn JS, 51:189
Seruca R, 53:97
Sessarego M, 52:43; 57:69
Sfikas K, 57:161
Shah N, 54:119
Shahbahrami B, 54:143
Sharma P, 51:235
Shaw HM, 51:45
Sheer D, 51:13
Shekhter-Levin S, 57:169
Sherer M, 57:169
Sheridan BL, 54:21
Sherwood JB, 54:267
Shiferaw S, 51:239
Shiina H, 56:65
Shikata I, 54:27
Shimada H, 56:31
Shiroozu A, 54:27
Shoffner RN, 54:205
Silva MLM, 56:171
Simoni G, 52:181
Śladkowska G, 56:7
Sleijfer DTh, 54:183; 57:59
Slovak ML, 56:237
Smadja N, 51:85; 52:123
Smialek B, 57:103
Smith AG, 55:35
Smyrk T, 53:143
Sobrinho-Simões M, 53:97; 54:137
Söderhäll S, 55:97
Sokolowska B, 55:173
Solé F, 51:41; 54:133; 55:133
Solh H, 55:85
Southwestern Oncology Group Leukemia Cytogenetics Subcommittee, 53:257
Sparkes RS, 56:143
Spurbeck JL, 56:231
Squicciarini P, 53:237
Sreekantaiah C, 51:195; 52:101; 52:193; 53:75; 53:125; 54:115; 54:173; 54:273; 55:163; 55:167
Stamberg J, 56:181
Standen GR, 52:201
Staroselsky AN, 56:209
Stefanini M, 51:89
Steinberg BM, 56:181
Stenman G, 55:19; 57:121
Stern C, 54:223
Sternes KL, 51:269; 56:73
Sterry W, 54:269
Stevens K, 51:273
Stillwell RG, 53:205
Stioui S, 52:181
Stone DM, 53:105
Story CJ, 56:255
Stratton MR, 53:101
Strigini P, 54:253
Stroh JA, 56:237
Stul M, 55:217
Stuppia L, 51:223
Suijkerbuijk RF, 57:219
Sumi H, 56:65
Sundareshan TS, 55:273
Sunderman FW Jr, 53:57
Surti U, 53:125; 53:199
Swanson CM, 53:119; 57:181

Tabilio A, 56:203
Tainaka T, 51:239
Tajara EH, 54:33; 55:73; 56:177
Takanari H, 51:155
Talpos G, 57:209
Taniwaki M, 54:77
Tanzer J, 57:231
Tarone RE, 57:1
Tarrida N, 51:41
Tast DE, 54:143
Tateishi R, 57:19
Tauchi T, 56:281
Taylor LD, 55:249
Tesch H, 56:243
Tharapel SA, 55:89
Thode B, 54:223; 56:277
Thomas J, 53:229
Thomé JA, 54:33; 55:73; 56:177
Thompson PW, 52:201; 55:269
Tilly H, 52:135
Timens W, 54:183
Timmons CF, 57:11
Tokunaga S, 51:67
Tomilin NV, 56:11
Tomlinson GE, 57:11
Tonini GP, 54:253
Toogood IRG, 51:255
Torlontano G, 51:223
Toyama K, 56:281
Tran TN, 56:31
Travagli JP, 52:157
Traweek ST, 56:237
Trujillo JM, 52:1
Tsao S-Y, 54:91
Tsunoda J, 57:53
Tully SM, 57:187
Tzeng C-C, 55:67

Ueyama T, 54:27

Valente AN, 56:171
Van Damme B, 55:191; 57:137
van den Berg E, 53:15; 54:183; 54:215
Vandenberghe E, 53:229
Van Den Berghe H, 51:279; 52:205; 53:229; 54:223; 55:115; 55:191; 55:217; 57:137
van der Hout AH, 51:121
van der Plas DC, 52:143
VanDevanter DR, 57:133
van de Ven W, 54:223
van Doormaal JJ, 53:15; 54:215

van Echten J, 57:219
van Echten-Arends J, 57:59
Van Gool S, 57:137
van Kessel AG, 57:219
Vanni R, 53:247
Vasselon C, 55:31
Vecchione D, 53:113
Vénuat A-M, 52:157; 53:23
Verhoef G, 55:217
Verma RS, 54:229; 57:175; 57:195
Vermeij A, 53:15; 54:215
Viegas-Péquignot E, 52:27; 56:23
Vig BK, 51:269; 56:73
Villegas A, 54:163
Vogel A, 57:133
Vos A-M, 53:15; 54:215
Vosburgh E, 57:201
Vredenburgh JJ, 54:233

Wagner J, 55:181
Wainscoat JS, 53:91
Waldman FM, 55:243; 57:93
Walgraeve D, 55:217
Wang CY, 52:51
Wang M, 51:215
Wang N, 54:205
Wang T-Y, 51:125
Watkins PC, 57:109
Watson P, 53:143
Wattel E, 51:85
Webb HD, 56:87
Webb T, 56:157
Wedell B, 55:19
Weichenthal M, 53:265
Weidner N, 55:163; 55:167
Weir-Thompson EM, 51:103
Wen W-N, 52:51
Wen ZQ, 55:277
Wenger SL, 54:263
Wennerberg J, 55:125
Wessels JW, 57:225
White L, 51:235
Whittaker JA, 55:269
Wiersema J, 54:215
Wiersema-Buist J, 57:59
Willén H, 55:11; 57:161
Willoughby M, 54:119
Woessner S, 51:41; 54:133
Wolman SR, 57:209
Wullich B, 52:165
Wurster-Hill DH, 54:233
Wyandt H, 57:201

Xiao H, 51:207
Xiao S, 55:197
Xue Y, 51:215

Yan F-C, 55:197
Yang-Feng TL, 54:129
Yasha TC, 55:273
Yatani R, 51:155
Yee G, 52:1
Ying KL, 56:31
Yip M-Y, 51:235
Yiu GKC, 54:91
Yoshida J, 54:27
Yoshida M, 57:53
Yoshida T, 51:155
Young BD, 57:109
Youngblom J, 54:205

Zafrani B, 52:27
Zaslav A-L, 56:181
Zehnbauer B, 55:181
Zhu W, 51:215
Zipf TF, 52:1
Zonta A, 52:85
Zukowski K, 52:51

Subject Index to Volumes 51–57

Acoustic Neuroma; see Neuroma
Acute Erythroleukemia (M6)
  chromosome changes, 51:1; 67
  drug susceptibility 51:67
  Fanconic anemia, 51:1
  normal karyotype, 51:67
Acute Lymphoblastic Leukemia (ALL)
  ABO groups in, 51:113; 56:7, 255
  ANLL after treated ALL, 55:85
  BCR rearrangements, 51:259
  BMT changes, 51:223
  CD7+, CD4−/CD8−, 56:171
  cell lines, 53:23
  childhood ALL, 55:249
  chromosomes in, 51:223, 259; 52:43, 107, 173; 54:197, 277, 55:249, 261
  cytogenetic samples in adults, 52:79
  cytogenetics of childhood ALL, 55:249, 261
  del(5)(q13q33) in, 52:173
  fluorodeoxyuridine synchronization, 52:107
  heterochromatin variability in children with, 54:67
  i(13q) in, 54:163
  "jumping" translocations, 56:223
  karyotypes and prognosis in intensive and specific therapy, 54:277
  methods of preparation, 52:93
  Ph+, 51:259, 52:43
  prognostic aspects, 54:277
  RB1 gene in Ph+ ALL, 54:197
  technical variables, 52:79, 93
  t(3;12)(q28;q13) in childhood ALL, 55:261
  t(4;11)(q21;p14–15) in ALL with T-cell and myeloid features, 56:255
  t(11;14)(p15;q11) in child, 56:171
  t(Y;2) in, 56:7
  variant Ph in, 51:260; 52:43
  9p in Ph genesis, 52:43
  19p in Ph+ ALL, 53:139
Acute Megakaryoblastic Leukemia (M7)
  chromosome changes, 51:1; 54:239
  Fanconi anemia, 51:1
  t(1;22)(p12–13;q13) in M7, 54:239
  t(16;21)(p11.2;q22) 53:83
Acute Monoblastic Leukemia; see Acute Monocytic Leukemia
Acute Monocytic Leukemia (AmoL) (M5)
  chromosome changes, 51:1, 67, 189; 54:61, 163; 55:97
  drug susceptibility, 51:67
  dup(12) in Down syndrome with, 55:97
  Fanconi anemia, 51:1
  in Down syndrome, 55:97
  normal karyotypes, 51:67
  t(8;14)(p11;q11.1) in M5b, 56:237
  t(9;11;16)(p22;q23;p13) in, 54:163
  t(16;21)(p11;q22) with erythrophagocytosis, 54:61
  t(21;21)(q22.1;q22.5) in, 54:163
  3q13.3 and "jumping" translocations, 51:189
Acute Myeloblastic Leukemia (AML) (M2)
  ABO groups in, 51:113
  chromosome changes in M1 and M2, 51:1; 67; 53:84; 54:163, 199; 56:281; 57:175
  drug susceptibility, 51:67
  inv(13)(p11q32) in M2, 54:163
  molecular studies of t(8;21), 57:109
  normal karyotypes, 51:67
  t(2;16) and +22 in M2 with eosinophilia, 56:281
  t(8;21) breakpoint deletions, 57:109
  t(8;21) by in situ hybridization, 57:103
  t(8;21) in M2, 57:103, 175
  t(11;22) of Ewing's sarcoma in ANLL case, 55:157
  t(16;21)(p11.2;q22) in, 53:83
  +4 and +9 in, 55:273
  +13 in males with ANLL, 57:79
  +13 in M1, 56:39; 57:79
  +13 in M2, 57:79
Acute Myelogenous Leukemia; see Acute Myeloblastic Leukemia
Acute Myeloid Leukemia; see Acute Nonlymphocytic Leukemia
Acute Myelomonocytic Leukemia (AMMoL) (M4)
  atypical t(7;19) in, 57:169
  childhood type, 57:195
  chromosome changes, 51:1, 67, 79, 235, 255; 53:84; 57:195, 225
  drug susceptibility 51:67
  early progenitor cell in t(4;11), 51:79
  Fanconi anemia, 51:1

© 1990 Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

Cancer Genet Cytogenet 57:247–270 (1990)
0165-4608/90/$03.50

inv(16) and t(16;16) have same breakpoints in, 57:225
inv(16)(p13q22), t(1;16)(q32;q22), 51:235
"jumping" translocations, 56:223
normal karyotypes, 51:67
t(3;inv(16)) with eosinophilia, 55:269
t(4;11)(q21;q23), 51:79
t(12;22)(p13;q12), 51:255
t(16;21)(p11.2;q22) in 53:83
+8,+8 in M4 after gastric cancer, 54:27
+13 in, 56:39
Acute Nonlymphocytic Leukemia (ANLL)
ABO groups in, 51:113
ANLL after ALL, 55:85
BMT changes, 51:223
childhood type, 57:195
chromosome changes, 51:1, 67, 79, 189, 223, 255; 52:1; 53:83; 54:199, 278; 55:119; 57:195
der(3)t(3;5) in ANLL (secondary?), 54:129
drug susceptibility, 51:67
evolving from myelofibrosis, 52:63
Fanconi anemia, 51:1
inv(16)(p13q22) in hypoplastic, 51:63
i(21q) in, 55:101
"jumping" translocations, 51:189
karyotypes and progression in intensive and specific therapy, 54:277
meaning of random changes, 53:257
method of preparation, 52:93
methodologic considerations, 52:93
molecular studies of t(8;21), 57:109
M2 with t(2;16),+22 and eosinophilia, 56:281
normal karyotype, 51:67
prognostic aspects, 54:277
response to therapy, 51:67
secondary, 55:119
therapy related, 55:119
trisomy 13q in, 55:107
t(8;20)(q13;q13), 52:1
t(8;21) by in situ hybridization, 57:103
t(12;22)(p13;q12) in M4, 51:255
t(16;21)(p11.2;q22) in ANLL, 53:83
11q23–24 translocations in, 55:160
+13 in, 56:39
Acute Promyelocytic Leukemia (APL) (M3)
chromosome changes in, 54:199, 57:53, 201
localization of breakpoints in t(15;17), 54:265
molecular studies of t(15;17), 54:265
second relapse, 57:53
t(1;3)(p36;q21) in APL, 57:53
t(1;15;17) in APL, 57:201
variant translocations in, 57:204
15q24 in, 54:265
Adenomas
chromosome changes in pleomorphic, 52:187
of breast, 52:224
of lacrimal gland, 55:125
of large bowel, chromosome number and DNA content, 53:219
of thyroid, 56:231; 277
pleomorphic, 52:187; 55:125
Adipose tissue
liposarcoma, 52:262
lipomas, 52:262
tumors, 52:262
Adrenal gland
cortical carcinoma, 56:125
cytogenetics of tumor, 56:125
familial? 56:125
Adult T-cell leukemia (ATL)
cytogenetics, 51:131
erb-B, 51:133
HTLV-1 carriers, 51:131
hypothesis of leukemogenesis, 51:131
pre-ATL, 51:131
Alveolar soft-part sarcoma
multiple and complex chromosome changes, 55:167
Anemia
aplastic in FA, 51:4
Fanconi, 51:1
refractory, 53:279
Angiofibroma
benign, 52:265
cytogenetics of, 52:265
from patients with tuberous sclerosis, 52:265
Angiomyxoma
cytogenetics of, 56:130
of pelvis, 56:130
Animal tumors
cytogenetic changes in mast cell tumors, 53:105
mast cell tumors in dogs, 53:105
metastasis behavior in mice, 54:205
rat mammary cancer, 56:104
study of "dominant" tumor clones in mice, 54:153
Astrocytoma
cytogenetics of, 52:251–252; 53:119; 55:225
evolution of chromosome changes, 53:119
tyrosine kinase growth factor receptors, 56:109
xanthoastrocytoma, pleomorphic, 55:225
Ataxia-Telangiectasia (AT)
cytogenetics of, 56:143
inversions of chromosome 14, 55:1
T-leukemia in, 55:1
T-PLL in, 55:1

Atherosclerotic lesions
cytogenetics of plaques, 52:260, 262
del(1)(p35) in, 52:262

Bands
by restriction enzymes, 56:102
C-bands in prostate cancer, 51:57
Basal cell carcinoma
cytogenetic changes, 52:216, 219–220; 54:33; 56:177
multiple clones, 52:219; 54:33
t(4;14) and inv(4) in, 52:220; 56:177
t(9;14),1q−,+5,+7, and −X, 54:33
Basophilic leukemia
Ph+, 51:215
t(8;21) and t(9;22), 51:15
B-cell
CLL and del(12)(p13), 51:125
evolution in CLL, 57:187
lymphomas (unusual), 53:229
BCR rearrangements
and residual leukemia, 52:19
in ALL, 51:259
in CML, 51:259; 56:189
in CML case with t(12;14), 56:189
in essential thrombocythemia, 54:21
in marrow engraftment, 55:181
in Ph+ acute leukemia, 51:259
in Ph-negative CML, 52:143; 56:189
in T-ALL, 51:259
studies in Ph+ leukemias, 57:143
Beckwith-Wiedemann syndrome
tumors in, 52:270
11p15.5 in, 52:270
Benign tumors
and "metastasis" gene, 54:139
chromosomes in, 54:139
nodular thyroid goiter, 55:73
Biphenotypic leukemia
acute form with t(14;19), 53:67
*bcl*3 in, 53:67
IgH gene, 53:67
t(14;19)(q32;q13.1) in, 53:67
Bladder
cell line, 36:138
chromosomes in tumors, 52:113, 231, 246; 56:65, 138
follow-up studies, 52:246
in-situ hybridization, 52:231, 245; 56:99
numerical changes of 1,7,9 and 11 in cases, 52:231
tumors, 52:113
unstable chromosome changes in cancer of, 56:65
Blastic phase of CML
after BMT, 57:69
busulfan induced SCE, 52:71
chromosome changes, 51:167; 52:143; 55:133; 57:69
in Ph-negative CML, 52:143
megakaryoblastic in Ph+ CML, 55:133
myeloid and lymphoid, 51:167
+Ph,+8,+17,+19 in, 51:167
SCE in, 52:71
study in India, 51:167
t(3;14)(q26;q11) in 55:133
Blastoma
chromosome changes, 56:136
pulmonary, 56:136
Blood groups
ABO in blood diseases, 51:113
in hematologic malignancies, 51:113
Bloom syndrome
biochemical aspects, 53:1
molecular aspects, 53:1
Bone cyst
aneurysmal, 56:119
chromosomes in, 56:119
Bone marrow
cytogenetic samples in ALL, 52:79, 93
direct vs culture method, 52:93
methodologic aspects in ANLL and ALL, 52:93
normal values, 55:39
significance of random changes, 53:257
technical variables in ALL, 52:79, 93
Bone marrow transplantation (BMT)
allogenic in Ph+ CML, 57:69
cytogenetic survey of 31 patients, 51:223
cytogenetics of donors, 55:39
engraftment, 55:181
eosinophilia in M4, 51:235
fluorodeoxyuridine synchronization in ALL, 52:107
for ALL, 51:223
for ANLL, 51:223
karyotype evaluation in Ph+ CML, 57:69
molecular and cytogenetic evolution of engraftment, 55:181
Brain
astrocytomas, 52:251–252; 53:119; 55:225
banding and immunostaining of tumors, 52:249
chromosome 22 in tumors, 52:248
cytogenetics of tumors, 52:251–254; 55:225; 56:126, 127, 128
deletion of chromosome 10, 56:127
ependymoma, 54:55
evolution of astrocytoma, 53:119
germ cell tumor with hematologic malignancy, 57:41
in oligodendrogliomas, 52:253–254
interphase cytogenetics, 52:248
tumors, 52:248–249, 251–254; 55:225
t(1;6)(q21;q13) in medulloblastoma, 53:101

xanthoastrocytoma, pleomorphic, 55:225
+7 and −Y not specific for gliomas, 52:249
Breast cancer and tumors
allelotype in, 52:217
cell lines, 51:239; 57:93; 56:96
chromosome changes, 51:183, 239; 52:113, 224; 53:205; 56:97, 141; 57:93
chromosome 17 in, 56:107
constitutional t(7;10)(q33;q26) in breast cancer, 56:114
deletion of chromosome 10, 56:127
HSR in, 52:218
in adenomas, 52:224
in male, 55:243
interphase studies, 55:243; 57:93
MCF-7 cell line analysis, 57:93
neuroendocrine tumors, 52:223
oncogenes, 51:239; 52:218, 224
1p13 in cancer, 52:217
3p, 6q, 11q, 16q, 17p and 19q in, 53:205
3p, 6 and 18q changes, 52:217
11p15, 51:183
11p23–24, 51:183
11q13 in breast cancer, 52:224
Bromodeoxyuridine (BrdU)
incorporation in MCF-7 cell line, 57:93
Burkitt lymphoma
effect of mitomycin C, 56:105
SCE in cells, 56:105

Cancer
animal research in, 53:137
BrdU catabolism and replication band pattern in cancer cells, 52:23
cytogenetics of solid tumors, 56:140
gene mapping in, 55:139
hereditary colon cancer, 53:143
hereditary ovarian cancer, 53:161
predisposition in Cockayne syndrome and XP, 57:1
Registry, 52:258
Registry of solid tumors, 52:258
SV-40 transformed human, 56:23
Carcinoids
of lung, 52:232
3p deletions in lung, 52:232
Carcinoma
cytogenetic changes in, 51:85
Merkel cell, 51:85
renal, 51:137
Cell lines
ALL lines, 53:23
B-cell CLL, 54:101
breast cancer, 51:239
chromosomes in nasal cell lines, 52:51
colonic adenoma and change to carcinoma, 56:111
derived from single cells, 56:73
"dominant" tumor cell clones, 54:153
Ewing sarcoma, 57:19
from osteosarcoma, 57:31
glioma with polysomy 22, 52:252
grown in nude mice, 53:45
hepatic cell lines from SV40-T antigen gene in transgenic mice, 55:207
HL-60 and c-*myc*, 56:57
MCF-7 breast cancer cell line, 57:93
meningioma, 52:256
murine melanoma, 56:209
nasal and nasopharyngeal immortalized by papillomavirus DNA, 52:51
oncogene changes in, 51:239
ovarian adenocarcinoma, 56:111
rhabdomyosarcoma (embryonal), 54:83
SEWA and C-band minus chromosomes, 56:98
small cell lung cancer, 52:282
stomach cancer, 55:67
Centromere
in neoplasia, 51:269
without kinetochore proteins, 51:269
Cerebral tumors
extragonadal germ cell tumor, 57:41
hematologic malignancy in cerebral germ cell tumor, 57:41
Cervix uteri
chromosomes in tumors, 52:113; 53:75
papillomavirus integration, 52:230
statistical approach to chromosome changes, 53:75
Chondrosarcoma
clear cell, 52:193
cytogenetic heterogeneity, 52:266
cytogenetics of, 52:193, 266–267
flow cytometry in, 52:193
9q22 in extraskeletal myxoid, 52:267
Chordoma
chromosome changes, 56:197
sacral, 56:197
Choroid plexus tumors
chromosome changes in, 56:128
identical karyotypes, 56:128
Chromosomal aberrations
endoreduplication, 51:155
induced by vincristine, 51:155
premature chromosome condensation, 51:155
Chromosome analysis
amniotic fluid, 52:12
blood and marrow, 52:13
cancer cells, 52:14
chorionic villi, 52:12
fragile X studies, 52:13
guidelines, 52:11
Chromosome anomalies

blastic phase of CML, 51:167
dup(1q) in FA with leukemia, 51:1
Fanconi anemia, 51:1
in ALL, 51:223; 52:43, 107, 173
in ANLL, 51:1, 79, 223, 255; 52:1
in astrocytoma, 53:119
in ATL, 51:131
in basal cell carcinoma, 52:220; 54:33; 56:177
in benign ovarian tumors, 52:230
in BMT, 51:223
in breast adenomas, 52:224
in breast cancer, 51:183, 239; 53:205
in cervical cancer, 53:75
in chondrosarcoma, 52:193; 267
in chordoma, 56:197
in clear cell sarcoma, 52:101
in CLL, 53:35; 55:49; 57:187
in CML, 51:167
in CMMoL, 55:57
in Ewing sarcoma, 52:273; 57:19
in fibrosarcoma, 52:37
in germ cell tumors, 52:278; 57:59
in head and neck tumors, 56:181
in hemangiopericytoma, 54:173
in Hodgkin disease, 51:103
in large bowel tumors, 52:233–235
in leiomyomas, 52:261; 53:125, 199, 247
in liposarcoma, 52:268, 269
in lung cancer, 52:231
in MDS, 51:73; 55:57; 56:203, 243
in melanoma, 52:218
in meningioma, 51:35
in MEN-1, 52:85
in Merkel cell tumor, 51:85
in mesoblastic nephroma, 52:272
in MFH, 52:258
in MPD, 51:73
in myxoid liposarcoma, 51:195
in neuroectodermal tumors, 51:13
in oligodendrogliomas, 52:253, 254
in ovarian cancer, 52:240, 242
in pancreatic cancer, 52:238
in parotid gland, 55:19
in plasma cell leukemia, 52:123, 135
in pleomorphic adenomas, 52:187
in rhabdoid tumor, 56:31
in sarcomas, 52:266
in schwannomas, 57:121
in small round cell tumors, 54:1
in solid tumors, 56:140
in squamous cell carcinoma, 52:220
in synovial sarcoma, 52:266, 267
in thymoma, 52:227
in thyroid adenomas, 52:157, 221; 56:231, 277
in thyroid cancer, 52:216, 221; 54:215; 56:231
in transformed mouse cells, 53:185
in tumors, 52:113
in uveal melanoma, 52:215
in XP, 51:89
induced by vincristine, 51:155
leukemia in FA, 51:1
numerical changes in tumors, 52:113
preleukemia in FA, 51:1
−7 in FA with leukemia, 51:1
Chromosomes
1 Alu variations in leukemia, 56:11
in bladder cancer, 52:231
in breast cancer, 52:217
in ependymoma, 54:55
in esophageal cancer, 55:197
in Ewing sarcoma, 52:271
in FA, 51:1
in hereditary melanoma, 51:45
in leiomyoma, 52:263; 53:247
in lymphoma, 53:229
in meningioma, 51:35
in Merkel cell carcinoma, 54:109
in MFH, 52:258
in neuroblastoma, 55:231
in pancreatic cancer, 52:238
in plasma cell leukemia, 52:123
in tumors, 52:113
in variant Ph, 51:167
in Wilms tumor, 52:270
1p in colorectal cancer, 56:45
1q trisomy in MDS, 56:243
2 Alu variations in leukemia, 56:11
in clear cell sarcoma, 52:101
in esophageal cancer, 55:197
in leiomyoma, 52:263; 53:247
in lymphoma, 53:113
in meningioma, 51:35
in nasal cells, 52:51
3 Alu variations in leukemia, 56:11
in acute monocytic leukemia, 51:189
in breast cancer, 53:205
in esophageal cancer, 55:197
in hereditary renal cell cancer, 51:121
in kidney cancer, 52:245
in MDS and ANLL, 54:129
in MFH, 52:258
in MPD with MDS features, 51:73
in nasopharyngeal cancer, 54:91
in pleomorphic adenomas, 52:187
4 in esophageal cancer, 55:197
in leiomyoma, 52:263
in tumors, 52:113
5 in ALL, 52:173
in large bowel cancer, 54:259
in liver cancer, 52:240
in Ph+ CML, 51:273

in therapy related acute leukemia, 55:119
in tumors, 52:113
6 Alu variations in leukemia, 56:11
identification by Alu-based PCR, 56:95
in breast cancer, 53:205
in CLL, 53:35
in endometrial polyp, 51:279
in leiomyoma, 55:11
in lymphoma, 53:229
in melanoma, 52:257
in myxoid liposarcoma, 52:268
in variant Ph, 51:167
7 in bladder cancer, 52:231
in esophageal cancer, 55:197
in FA, 51:1
in gynecologic tumors, 55:89
in leiomyoma, 52:261, 263; 53:125; 55:11
in MEN-1, 52:85
in preleukemia of Down syndrome, 54:119
in therapy related acute leukemias, 55:119
in tumors, 52:113
in variant Ph, 51:167
8 Alu variations in leukemia, 56:11
in acute monocytic leukemia, 51:189
in breast cancer, 52:27
in CML, 51:167; 52:71
in gastric cancer, 54:137
in hepatoblastoma, 51:281
in myelofibrosis, 52:63
in myxoid liposarcoma, 51;195
in plasma cell leukemia, 52:123
+8 in esthesioneuroblastoma, 57:133
+8,+8 in M4, 54:27
9 in bladder cancer, 52:231
in chondrosarcoma, 52:267
in myeloma, 55:175
in Ph+ ALL, 52:43
9p in Ph+ ALL, 53:139
10 Alu variations in leukemia, 56:11
in Pyronie disease, 52:181
in renal cancer, 51:137
in thyroid adenomas, 52:157; 53:15
in thyroid cancer, 53;15; 55:73; 57:209
in tumors, 52:113
in variant Ph, 51:167
10p translocation detected by hybridization, 56:23
11 Alu variations in leukemia, 56:11
in ANLL translocations, 55:160
in Beckwith-Wiedemann syndrome (BWS) and its tumors, 52:270
in bladder cancer, 52:231
in breast cancer, 51:183; 53:205
in Ewing sarcoma, 52:273
in fibrosarcoma, 52:37
in germ cell tumors, 52:277
in MFH, 52:258
in ovarian cancer, 52:243
in plasma cell leukemia, 52:173
in rhabdomyosarcoma, 54:1
in therapy related acute leukemia, 55:119
in tumors, 52:113
in Wilms tumor, 52:270
12 in B-CLL, 51:125; 55:49
in esophageal cancer, 55:197
in female genitourinary tumors, 54:273
in leiomyoma, 53:125, 247; 54:273; 55:11
in lymphoma, 53:229
in tumors, 52:113
in variant Ph, 51:167
i(12p) and 12q− in germ cell tumors, 52:278
i(12p) in germ cell tumor in streak gonad, 57:219
Not-1 end clones, 52:280
+12 in benign ovarian tumors, 52:230
13 del(13) in leiomyoma, 53:199
del(13q) in osteosarcoma from case with retinoblastoma, 57:31
in acute leukemia with lineage inconsistency, 55:107
in leiomyosarcoma, 54:115
in MDS, 55:149
in plasma cell leukemia, 52:173
in rhabdomyosarcoma, 55;257
+13 in males with ANLL, 57:79
14 Alu variations with leukemia, 56:11
in AT with leukemia, 55:1
in CMMoL, 52:139
in leiomyoma, 52:263; 53:247, 55:11
in lymphoma, 53:229
in neuroblastoma, 55:231
in plasma cell leukemia, 52:123
in tumors, 52:113
14q11 in ATL, 51:133
15 Alu variations in leukemia, 56:11
15p in giant cell tumor of bone, 57:161
16 Alu variations in leukemia, 56:11
in acute leukemia, 51:63
in AMMoL, 51:235
in breast cancer, 53:205
+16 in HD, 51:103
16q22 in translocation in ANLL, 56:281

17 in breast cancer, 52:223; 53:205
in Ph+ CML, 52:71
in thyroid adenomas, 52:157
in tumors, 52:113
18 breakpoints on 18 in t(14;18), 55:135
in lymphoma, 54:233–234
in MEN-1, 52:85
in tumors, 52:113
19 CEA gene at 19q13.2, 54:77
in breast cancer, 53:205
in CML, 51:167; 52:71
in leiomyoma, 53:248
in ovarian tumors (19p+), 52:242
in tumors, 52:113
19q in giant cell tumor of bone, 57:161
20 in fibrosarcoma, 52:37
in tumors, 52:113
21 in CMMoL, 51:139
in therapy related acute leukemia, 55:119
in tumors, 52:113
iso(21q) in hematologic disorders, 55:101
22 in brain tumors, 52:248
in clear cell sarcoma, 52:101
in Ewing sarcoma, 52:273
in leiomyomas, 52:247; 53:125, 247
in meningioma, 51:35; 52:250
in neuroectodermal tumor, 51:13
−22 in acoustic neuroma, 56:87
Chronic Lymphocytic Leukemia (CLL)
ABO groups in, 51:113
cell line, 54:101
chromosome changes in, 53:35; 55:49; 57:187
chromosome 6 in, 53:35
c-*myc* and K-*ras*-2 in, 51:125
del(12)(p13) in, 51:125
extra #11 and behavior of CLL cell lines, 54:101
homozygote breakpoint at 13q14, 57:231
karyotypic evolution, 57:187
translocations in, 53:35; 55:49
+12 and +21 in, 51:207
13q14 in CLL, 57:231
+Y in, 51:207
Chronic Lymphoproliferative Disorders
B-cell, 51:207
chromosomes in, 55:49
+12 and +21, 51:207
+Y in, 51:207
Chronic Myelocytic (Myelogenous) Leukemia (CML)
ABO groups in, 51:113
after I^{131} therapy, 55:217
basophilic leukemia with t(8;21) and t(9;22), 51:215
BCR studies, 52:143; 54:247; 57:143
blastic phase, 51:168; 57:69
bone marrow transplantation (BMT), 57:69
busulfan induced SCE, 52:71
chromosomal characteristics, 51:167, 273; 52:143; 54:199, 247; 56:243; 57:69, 139
chronic phase, 51:167
complex translocations, 57:143
cytogenetics of Ph-negative CML, 52:143
in Hodgkin disease, 55:277
karyotype evolution after BMT, 57:69
long survival, 57:69
megakaryoblastic transformation, 55:133
megakaryocytosis and +5, 51:273
molecular (BCR) studies, 52:143; 54:247; 57:143
Ph+ CML after I^{131} therapy of thyroid cancer, 55:217
Ph-negative, 52:143
+Ph,+8,+17,+19 in BP, 51:167
SCE in, 52:71
secondary Ph+ CML, 55:217, 277
study in India, 51:167
t(3;14)(q26;q11) in megakaryoblastic blastic phase, 55:133
t(3;21) in crisis, 57:153
variant Ph chromosomes, 51:169; 54:247; 57:139
1q trisomy in, 56:243
+5 in Ph+ CML, 51:273
Chronic myelomonocytic leukemia (CMMoL)
blastic phase, 55:57
chromosome changes in, 55:57
del(15)(q11q15) in, 55:35
dup of der(21) in, 51:139
eosinophilia in, 51:277
i(14q) in, 52:139
t(5;12) and eosinophilia, 51:277
t(8;21)(q22;q22) in, 51:139
+8, −Y, −7/7q− and 12p−, 55:57
−Y in, 52:139; 55:57
Clear cell hidradenoma (sweat gland carcinoma)
t(6;22)(p22;q12) in, 52:226
Clear cell sarcoma
chromosomes 2 and 22, 52:101
malignant melanoma of soft parts, 52:101
tendons and aponeuroses, 52:101
Cockayne syndrome
cancer predisposition, 57:1
group C fibroblasts, 57:1
radiation induced chromatid aberrations, 57:1
Colorectal tumors; see Large bowel
Constitutive heterochromatin

C-bands, 51:57
in prostate cancer, 51:57
Cytogenetic changes
blastic phase of CML, 51:167
dup(1q) in FA with leukemia, 51:1
Fanconi anemia, 51:1
in ALL, 51:223; 52:43, 107, 173
in ANLL, 51:1, 79, 223, 255; 52:1
in astrocytoma, 53:119
in ATL, 51:131
in basal cell carcinoma, 52:220; 54:33; 56:177
in benign ovarian tumors, 52:230
in BMT, 51:223
in breast adenomas, 52:224
in breast cancer, 51:183, 239; 53:205
in cervical cancer, 53:75
in chondrosarcoma, 52:193; 267
in chordomas, 56:197
in clear cell sarcoma, 52:101
in CLL, 53:35; 55:49; 57:187
in CML, 51:167
in CMMoL, 55:57
in Ewing sarcoma, 52:273; 57:19
in fibrosarcoma, 52:37
in germ cell tumors, 52:278; 57:59
in head and neck tumors, 56:181
in hemangiopericytoma, 54:173
in Hodgkin disease, 51:103
in large bowel tumors, 52:233–235
in leiomyomas, 52:261; 53:125, 199, 247
in liposarcoma, 52:268, 269
in lung cancer, 52:231
in MDS, 51:73; 55:57, 56:203, 243
in melanoma, 52:218
in meningioma, 51:35
in MEN-1, 52:85
in Merkel cell tumor, 51:85
in mesoblastic nephroma, 52:272
in MFH, 52:258
in MPD, 51:73
in myxoid liposarcoma, 51:195
in neuroectodermal tumors, 51:13
in oligodendrogliomas, 52:253, 254
in ovarian cancer, 52:240, 242
in pancreatic cancer, 52:238
in parotid gland, 55:19
in plasma cell leukemia, 52:123, 135
in pleomorphic adenomas, 52:187
in rhabdoid tumor, 56:31
in sarcomas, 52:266
in schwannomas, 57:121
in small round cell tumors, 54:1
in solid tumors, 56:140
in squamous cell carcinoma, 52:220
in synovial sarcoma, 52:266, 267
in thymoma, 52:227
in thyroid adenomas, 52:157, 221; 56:231, 277
in thyroid cancer, 52:216, 221; 54:215; 56:231
in transformed mouse cells, 53:185
in tumors, 52:113
in uveal melanoma, 52:215
in XP, 51:89
induced by vincristine, 51:155
leukemia in FA, 51:1
numerical changes in tumors, 52:113
preleukemia in FA, 51:1
−7 in FA with leukemia, 51:1

Deletions
chromosome 2 in lymphoma, 53:113
del(2)(p23) in M2, 57:175
del(5)(q13q33) in ALL, 52:173
del(6) in CLL, 53:35
del(6) in myxoid liposarcoma, 52:268
del(11q) and (18q) in MDS, 56:203
del(12)(p13) in CLL, 51:125
del(13p) in osteosarcoma of case with retinoblastoma, 57:31
del(13p) in thyroid adenoma, 56:277
del(15) in CMMoL, 55:35
in ANLL of FA, 51:1
in APL (M3), 57:204
in astrocytomas, 52:252
in BP of CML, 51:170
in breast cancer, 53:205
in CMMoL, 55:57
in colorectal cancer, 56:45
in esophageal cancer, 55:197
in Hodgkin disease, 51:105
in leiomyomas, 53:248; 55:11
in M2, 57:175
in pancreatic cancer, 52:238
in parotid gland cancer, 55:19
in Ph+ CML, 57:69
in schwannomas, 57:121
in uterine leiomyomas, 53:125
of +7 in preleukemia of DS, 54:119
5q− in large bowel cancer, 54:259
9p− in Ph+ ALL, 53:139
Desmoid tumors
cytogenetic findings, 56:122
5q in, 56:122
Dicentrics
dic(3;22)(p11;p11 or 12) in thyroid cancer, 54:218
dic(5;5)(p15.3;p15.3) in germ cell tumor, 57:59
dic(7;14)(q11;p11) in neuroectodermal tumor, 51:13
dic(Y;18) in acute leukemia, 52:165
+dic(11;19)(p15;q13) in giant cell tumor of bone, 56:263

idic(18q) in lymphoma, 54:233
idic(22;22)(p11;p11) in thyroid cancer, 54:215
in giant cell tumor of bone, 57:161
in Hodgkin diseases, 51:105
in kidney and bladder cancers, 56:65
DNA
and cytogenetics of pediatric tumors, 56:112
content and karyotype in solid tumors, 56:112
content in colorectal adenomas, 53:219
content in MCF-7 breast tumor cell line, 57:93
content in mediastinal germ cell tumor, 54:183
recombinant analysis in marrow engraftment, 55:181
sequences in YAC of chromosome 21, 57:109
Double Minute Chromosomes (DMS)
in a lipoma, 52:264
in bladder and kidney cancers, 56:65
in giant cell tumor of bone, 57:161
in medulloblastoma, 57:181
in neuroblastoma, 55:231
in prostate cancer, 55:79
molecular analysis, 57:181
Down syndrome
acute monocytic leukemia in, 55:97
loss of all or part of #7, 54:119
preleukemia, 54:119
47,XX,+21,dup(12),dup(12) in, 55:97
Drugs
chromosome changes, 51:155
vincristine and chromosome changes, 51:155
Duplications
dup(12) in M5 of Down syndrome, 55:97
in ANLL of FA, 51:1
in Hodgkin disease, 51:105
1q in MDS, 56:243
Dysplastic Nevi
and melanoma, 51:45

Enchondroma
cytogenetic findings, 56:119
t(12;15) in, 56:119
Endometrium
clonal changes in sarcoma, 55:163
normal karyotypes in adenocarcinomas, 52:242
numerical changes in early tumors, 55:89
polyps of, 51:279; 56:131
translocations in sarcoma, 55:163
t(6;20)(p21;q13) in, 51:279; 56:131
6p in, 51:279
+7 in, 55:89
Ependymoma
myxopapillary, 54:55
1p in, 54:55
Erythroleukemia
chromosome changes, 51:3, 67; 54:11
drug susceptibility, 51:67
Fanconi anemia, 51:1
normal karyotypes, 51:67
secondary with near-triploid karyotype, 54:11
Esophageal tumors
cytogenetic study, 55:197
12p- in cancer, 55:197
Essential thrombocythemia
distinct entity from CML, 54:21
Ph+ and *bcr*+, 54:21
Esthesioneuroblastoma
+8 in, 57:133
Ewing sarcoma
cell line, 57:19
chromosomes in, 52:273; 54:4; 56:96; 57:19
loss of heterozygosity at 1p, 52:271
molecular studies, 52:271, 273; 57:19
studies of cell line, 57:19
t(10;11;22)(p11;q24;q12) in, 56:96
t(11;22)(q24;q12) in, 54:4; 57:19
t(11;22)(q24;q12) in ANLL case, 55:157

Familial conditions
gastric polyposis, 53:97
melanoma, 53:237
SCE in familial melanoma, 53:237
Fanconi Anemia
acute megakaryoblastic leukemia (M7), 51:1
AML (M1 and M2), 51:1
AMMoL (M4), 51:1
AMoL (M5), 51:1
ANLL, 51:1
erythroleukemia (M6), 51:1
International Registry, 51:1
leukemia in, 51:1
MDS in, 52:201
preleukemia in, 51:1
Review 51:1
transient t(Y;1)(q12;q21) in, 52:201
Fibroblasts
chromosome changes in, 51:89
in Cockayne syndrome, 57:1
in MEN-1, 52:85, 222
in XP, 51:89; 57:1
Fibrohistiocytic tumors
cytogenetics of, 52:268
dermatofibrosarcoma protuberans, 52:268

MFH, 52:268
plexiform, 52:268
Fibrosarcoma
congenital, 52:37
cytogenetics of, 52:37
Fluorescence in situ hybridization (FISH); see also In situ hybridization
chromosome 12 in germ cell tumors, 56:95
detection of translocations, 56:23, 94
identification of markers, 52:165; 56:93
in bladder cancer, 56:99
in breast cancer line, 56:96
in Ewing sarcoma, 56:96
in somatic cell hybrids, 56:94
of inv(16) and t(16;16) in M4, 57:225
study of breakpoints in 16p in M4eo, 57:225
study of Rb gene, 56:98
VIM gene and 10p, 56:23
Yq probe, 52:165
Follicular lymphoma
chromosome changes in, 53:113
del(2), 53:113
Fragile sites
and active genes on X, 54:71
biologic agents and induction, 54:127
common on X-chromosome, 54:71
genetic activity and, 55:113
induction of breaks, 54:39
synergism between aphidicolon and adenoviruses, 54:39
3p14 in von Hippel-Lindau syndrome, 56:157
Fourth International Workshop on Chromosomes in Solid Tumors
Abstracts, 56:93–142
Conference Overview, 56:89
Preface, 56:87

Gallbladder
cholangiocarcinoma cell line, 56:139
karyotypic stability in cancer, 56:139
Gastric Carcinoma; see Stomach
Gastrointestinal tumors
breast cancer pS2 protein in, 56:107
pS2 in colon cancer, 56:107
pS2 in stomach cancer, 56:107
Gene mapping
CEA gene at 19q13.2, 54:77
in cancer, 55:139
Genes
loss of chromosome 17, 57:229
loss of p53 in solid tumors, 57:229
Germ cell tumors; also see Testis
blood disorder after therapy, 52:281
chromosome changes in, 52:278; 57:59, 209
chromosome 1, 52:271
del(9)(q21;q22) in, 54:188
extragonadal (cerebral), 57:41
hematologic malignancy in extragonadal, 57;41
hematopoietic activity in mediastinal tumor, 54:183
in gonadal dysgenesis, 57:219
in situ hybridization for malignant cells in seminal fluid, 52:271
in situ studies with chromosome 12, 56:95, 97
in streak gonad, 57:219
i(12p) and 12q- in, 52:278
lymphocytes in familial cases, 52:281
mediastinal, 54:183
NOR studies, 52:280
pediatric, 56:129
suppressor genes in, 52:277
teratoma components, 57:59
+7,+i(12p) in, 57:219
11p13 in, 52:279
Giant cell tumor of bone
chromosome changes, 57:87; 161
double minutes in, 57:161
growth factor overexpression, 56:263
significance of chromosome changes, 57:87
telomere association, 56:263; 57:161
TGF expression, 56:263
Gliomas; also see Brain
cell line with polysomy 22, 52:252
cytogenetics of, 52:253; 55:225; 56:128
xanthoastrocytoma, pleomorphic, 55:225
+7 and −Y (−X) not tumor specific, 52:249
Gonadal dysgenesis
germ cell tumor in streak gonad, 57:219
mixed, 57:219
XY female with tumor, 57:219
+7,+i(12p) in tumor, 57:219
Gynecologic tumors; also see Ovary and Uterus
chromosome changes, 55:89
early changes, 55:89

Hairy Cell Leukemia (HCL)
ABO groups in, 51:113
+12 and +21, 51:207
+Y, 51:207
Head and Neck Tumors
cytogenetics of carcinoma, 56:181
Hemangiopericytoma
chromosomes in, 54:173
t(12;19)(q13;q13.3) in, 54:173
Hepatoblastoma
chromosome changes, 51:281
i(8q) in, 51:281

Hepatocellular cancer; see Liver
Hereditary states
colon cancer, 53:143
dysplastic nevi, 51:45
fibroblasts in XP, 51:89
genetics, pathology, natural history and cancer control of colon cancer, 53:143
kidney cancer, 51:121
melanoma, 51:45
ovarian cancer, 53:161
pedigree studies in ovarian, 53:161
X-linked lymphoproliferative disease, 51:143
Heterochromatin
constitutive, 51:57
in prostate cancer, 51:57
variability in children with ALL, 54:67
Hodgkin Disease (HD)
ABO groups in, 51:113
chromosome changes, 51:103
immunoglobulin gene rearrangements, 51:103
Lennert lymphoma in treated, 56:116
nodular thyroid hyperplasia after irradiation of, 53:15
secondary Ph+ CML in, 55:277
Homogeneously staining regions (HSR)
in breast cancer, 52:27, 218
in lipoma, 52:264
in neuroblastoma, 55:231
in 8p1 in breast cancer, 52:27
lack of gene amplification in, 52:27
Hydatidiform moles
complete, 54:143
molecular genetics, 54:143

Immunoblastic lymphoma
chromosome changes in, 53:113
del(2), 53:113
Immunoglobulin
gene rearrangements in HD, 51:103
In-situ hybridization
chromosome 1 in prostate cancer, 52:247
chromosome 11 in tumors, 52:273
chromosome 12 in germ cell tumors, 52:279; 56:95
gene mapping, 52:274; 55:139
identification of markers, 52:165, 245; 56:93
in bladder cancer, 52:231, 245
in Ewing sarcoma, 52:273
in germ cell tumors, 56:95, 97
in MCF-7 breast cancer line, 57:93
in renal cancer (3p), 51:121
in seminal fluid (#1), 52:271
nonradioactive, 52:165, 225, 245, 274; 56:93, 94
t(8;21) in ANLL (M2), 57:103
whole chromosome paint probes, 56:93
yeast artificial chromosomes, 52:225
Yq specific DNA probe, 52:165
Interleukin-3
effects on mitotic index and karyotype of hemopoietic cells, 55:235
recombinant, 55:235
Interphase studies
cytogenetics, 52:225, 248
in bladder tumors, 52:231, 245
in brain tumors, 52:248
in male breast cancer, 55:243
in prostate cancer, 52:247
in renal cancer, 51:121
in situ hybridization, 51:23; 52:225, 248, 274
nuclei studies, 51:23
Inversions
in AT, 56:144
in giant cell tumor of bone, 57:161
in M4, 57:195
in Ph+ CML, 57:69
inv(3) in Ph+ CML, 57:72
inv(4)(p14q25) in basal cell carcinoma, 52:220; 56:177
inv(8)(p23q12) in pleomorphic adenoma, 52:189
inv(10)(p11q22) in pleomorphic adenoma, 52:189
inv(13)(p11q32) in M2, 54:166
inv(14) in cancer of larynx, 56:184
inv(14) in T-PLL and T-leukemia in AT patients, 55:1
inv(14)(q11.2q32.1) in T-lymphoma, 54:269
inv(16) in M4, 55:269; 57:195
inv(16)(p13q22) in acute leukemia, 51:63, 235
inv(20)(p12;q11) in thyroid adenoma, 52:161
in neuroectodermal tumors, 51:21
Isochromosomes
i(1q) in neuroectodermal tumors, 51:16
i(7q) in MDS of FA, 51:4
i(8q) in gastric cancer, 54:137
i(8q) in hepatoblastoma, 51:281
i(12p) in testicular tumors, 52:113, 278; 57:59
i(13q) in ALL, 54:166, 168
i(14q) in RA, 54:133
i(17q) in ALL, 56:7
i(17q) in CML-blastic phase, 51:167
i(17q) in lung adenocarcinoma, 52:231
i(17q) in medulloblastoma, 54:1; 57:181
i(17q) in preleukemia of DS, 54:119
idic(18q) in lymphoma, 54:233
in Hodgkin disease, 51:105

in vaginal cancer, 55:153
21q in hematologic diseases, 55:101

Karyotypic abnormalies
blastic phase of CML, 51:167
dup(1q) in FA with leukemia, 51:1
Fanconi anemia, 51:1
in ALL, 51:223; 52:43, 107, 173
in ANLL, 51:1, 79, 223, 255; 52:1
in astrocytoma, 53:119
in ATL, 51:131
in basal cell carcinoma, 52:220; 54:33, 56:177
in benign ovarian tumors, 52:230
in BMT, 51:223
in breast adenomas, 52:224
in breast cancer, 51:183, 239; 53:205
in cervical cancer, 53:75
in chondrosarcoma, 52:193; 267
in chordomas, 56:197
in clear cell sarcoma, 52:101
in CLL, 53:35; 55:49; 57:187
in CML, 51:167
in CMMoL, 55:57
in Ewing sarcoma, 52:273; 57:19
in fibrosarcoma, 52:37
in germ cell tumors, 52:278; 57:59
in head and neck tumors, 56:181
in hemangiopericytoma, 54:173
in Hodgkin disease, 51:103
in large bowel tumors, 52:233–235
in leiomyomas, 52:261; 53:125, 199, 247
in liposarcoma, 52:268, 269
in lung cancer, 52:231
in MDS, 51:73; 55:57; 56:203, 243
in melanoma, 52:218
in meningioma, 51:35
in MEN-1, 52:85
in Merkel cell tumor, 51:85
in mesoblastic nephroma, 52:272
in MFH, 52:258
in MPD, 51:73
in myxoid liposarcoma, 51:195
in neuroectodermal tumors, 51:13
in oligodendrogliomas, 52:253, 254
in ovarian cancer, 52:240, 242
in pancreatic cancer, 52:238
in parotid gland, 55:19
in plasma cell leukemia, 52:123, 135
in pleomorphic adenomas, 52:187
in rhabdoid tumor, 56:31
in sarcomas, 52:266
in schwannomas, 57:121
in small round cell tumors, 54:1
in solid tumors, 56:140
in squamous cell carcinoma, 52:220
in synovial sarcoma, 52:266, 267
in thymoma, 52:227
in thyroid adenomas, 52:157, 221; 56:231, 277
in thyroid cancer, 52:216, 221; 54:215; 56:231
in transformed mouse cells, 53:185
in tumors, 52:113
in uveal melanoma, 52:215
in XP, 51:89
induced by vincristine, 51:155
leukemia in FA, 51:1
numerical changes in tumors, 52:113
preleukemia in FA, 51:1
−7 in FA with leukemia, 51:1
Kidney tumors
changes in normal kidney cells, 56:133
chromosome changes, 56:134; 57:11, 137
familial, 56:135
hereditary cancer, 51:121; 56:135
in child, 57:137
i(12p) in gonadal germ cell tumor, 57:219
mesoblastic nephroma, 52:272
molecular analysis, 52:245
oncocytoma, 56:134
SCE in kidney cells and, 52:244
t(3;8) in renal cell carcinoma, 51:121; 56:135
t(6;17) in, 57:137
unstable chromosome changes in cancer, 56:65
3p in cancer, 52:245
+10 in renal cell carcinoma, 51:137
X,Y,7 and 10 changes in normal kidney cells in cancer, 52:244
Xp11.2 as recurring breakpoint, 57:11
Kinetochore
cytogenetic variability and kinetochore proteins, 56:73
neoplasia, 51:269
proteins, 51:269

Lacrimal gland
carcinoma in a pleomorphic adenoma, 55:125
chromosomes in tumor, 55:125
Large bowel
adenomatous polyposis coli, 52:229; 53:219
chromosome number in adenomas, 53:219
chromosome 5 in cancer, 54:259
chromosomes in cancers, 52:233–235
chromosomes in sporadic adenomas, 52:233
chromosomes in tumors, 52:113, 227, 233
DNA content in adenomas, 53:219
genetics, pathology and natural history

of cancer, 53:143
hereditary nonpolyposis cancer, 53:143
lck oncogene in, 52:236
metabolic pathway imbalance, 52:227
molecular studies, 52:233–234
tumors, 52:113
1p deletions and UMPK and PGD, 56:45
5q12-22 in cancer, 54:259
Larynx
cytogenetics of tumors, 56:181
Leiomyomas
cytogenetics subgroups, 56:118
cytogenetics of, 52:261, 263; 53:125, 199, 247; 53:125; 54:223; 55:11; 56:118
del(7) in uterine, 53:125; 55:11
del(13) in, 53:199
double translocation, 56:118
molecular studies, 54:223
of uterus, 52:261, 263; 53:125, 199, 247; 55:11
ring chromosomes in, 55:13
transformation in vitro of cells with 12q15 changes, 54:223
t(12;14), +12 and 7q− in, 52:261; 55:11
+12 in, 54:273; 55:11
−22 in, 53:127
Leiomyosarcoma
ring(13)(p11q34) in, 54:115
small bowel, 54:115
Leukemia
ABO groups in, 51:113
acute with lineage inconsistency and trisomy 13q, 55:107
Alu variations, 56:11
biphenotypic with t(14;19), 53:67
detection of minimal disease, 52:19
Fanconi anemia, 51:1
inv(16)(p13q22) in hypoplastic, 51:63
Lipoma
complex translocation, 52:264
"jumping" translocation, 52:264
molecular studies, 52:262
t(3;12)(q28;q24) in, 52:262
Liposarcoma
chromosome changes and histology, 56:117
chromosome changes in, 52:268–269; 56:117
cytogenetic heterogeneity, 52:266
del(6)(q14q24) in myxoid, 52:268
molecular studies, 52:262
t(12;16)(q13;p11), 51:195; 52:262, 266, 268, 269
+8 as nonrandom secondary change, 51:195
Liver
chromosome 5 allele loss in cancer, 52:240
hepatocellular carcinoma, 52:240
Loss of heterozygosity
at 1p in Merkel cell carcinoma, 54:109
at 3p in nasopharyngeal cancer, 54:91
at 11p in rhabdomyosarcoma, 54:1
at 17p13 in breast cancer, 52:223
chromosome loss in tumor progression, 52:241
in breast cancer, 52:217, 223, 241
in bronchogenic tumors, 52:212
in Ewing sarcoma (1p), 52:271
in melanoma, 56:101
in meningioma, 53:271
in osteosarcoma, 52:212
in testicular tumors, 52:278
of chromosome 5 in liver cancer, 52:240
of chromosome 13 and 17 in osteosarcoma, 53:45
Lung cancer
cell line of SCLC, 52:282
chromosome changes in adenocarcinoma, 52:231; 56:136, 137
in adenosquamous carcinoma, 52:231
molecular genetics, 52:228
non-small cell, 56:136, 137
PTHrP in lung cancer, 56:108
suppressor gene, 52:228
Lymphocytes
chromosome changes in MEN-1, 52:85
in familial testicular cancer, 52:281
in MEN-1, 52:85; 52:222
Lymphoma
ABO groups in, 51:113
B-cell (unusual), 53:229
breakpoints on 18 in t(14;18), 55:135
chromosome changes in, 53:113, 229; 54:233, 269; 57:47
chromosome changes in Saudis, 56:115
deletions of chromosome 2, 53:113
der(6)t(6;7)(q13;p13) in T-cell lymphoma, 54:269
diffuse large cell, 53:114; 54:233
follicular, 53:114
idic(18q) in marrow of diffuse large cell, 54:233
immunoblastic, 53:114
immunophenotypic features, 53:229
Lennert in HD, 56:116
lymphoblastic, 57:47
mycosis fungoides, 53:114
secondary changes in t(14;18), 56:116
Sézary syndrome, 53:114
splenic involvement, 57:47
t(10;11)(p13;q21) in histiocytic, 52:273
t(14;18) in, 57:47

Malignant Fibrous Histiocytoma (MFH)
chromosome changes, 52:258
cytogenetic heterogeneity, 52:266
DNA changes in, 56:101, 104
ring chromosomes, 52:258
1q11, 11p11, 19p13, 1p36 and 3p12 in, 52:258
Medulloblastoma
chromosomes in, 54:3, 57:181, 235
del(9) and del(11) in, 57:235
DMS in, 54:3; 57:181
in an adult, 57:235
i(17q) in, 54:3, 57:181
molecular aspects, 54:3; 57:181
t(1;6)(q21;q13) in cerebellar, 53:101
Megakaryocytes and megakaryopoiesis
abnormal in MPD, 51:73
chromosome changes in, 51:73
dysmegakaryopoiesis and translocations with chromosome 3, 51:73, 77
megakaryocytosis and +5 in Ph+ CML, 51:273
Melanoma
absence of linkage with 1p, 51:45
chromosome changes, 52:218, 257; 56:101
chromosome 6, 52:257
effects of UV on SCE in families, 53:265
hereditary, 51:45; 53:237
in Australia, 52:45
molecular analysis, 52:257; 56:101
murine, 56:209
of soft parts, 52:101
oncogene locus in Xiphophorus, 52:215
oncogene *myb*, 52:219
SCE in familial cases, 53:237, 265
SCE in relatives of melanoma patients, 53:265
uveal, chromosome changes, 52:215
Meningioma
atypical, 51:35
cell line, 52:256
cloning of 22q12.3–qter, 52:256
c-sis and PDGF in, 56:109
cytogenetic findings, 51:35; 52:250, 255; 56:100, 122, 123
hyperdiploidy in, 52:255
loss of heterozygosity of #22 DNA, 53:271
"meningioma region: at 22q12.3–qter, 56:99
suppressor gene, 52:250; 56:100
t(4;22) in, 52:250
uveal and −3,+8, 56:123
−22, 51:38
Merkel Cell Carcinoma
bone marrow metastasis, 51:85
cytogenetics, 51:85
loss of heterozygosity at 1p, 54:109
Mesoblastic Nephroma; also see Kidney
chromosome changes, 52:272
Ha-ras and INS, 52:272
loss of heterozygosity at 11p15.5, 52:272
Mesothelioma
t(X;12) in, 55:115
Metastasis
changes during multiple cycles, 54:205
chromosomal evolution in, 54:205
potential in murine melanoma, 56:209
Methods
banding and immunostaining of brain tumors, 52:249
bands by restriction enzymes, 56:102
calculation of bleomycin doses, 53:281
concentration of cells in ALL, 52:79
fluorodeoxyuridine synchronization in ALL, 52:107
for bladder cells, 52:246
G-banding improvement, 51:41
GCT conditioned media and masking of changes in tumors, 56:117
guidelines for chromosome analysis, 52:11
in adult ALL, 52:79
in ALL, 52:79
in-situ hybridization, 51:23; 52:274
MAC method, 51:41
methods in ANLL and ALL, 52:93
sample type in ALL, 52:79
somatic cell hybrids, 52:274
technical considerations, 52:93
technical variables in ALL, 52:79, 93
transit time in ALL, 52:79
use of biotinylated DNA probes, 51:23
Molecular studies
Alu variations in neoplasia, 56:11
amplification of chromosome 6 sequences, 56:95
biotinylated DNA probes, 51:23
cloning of 22q13–qter of meningioma, 52:256
detection of VIM gene, 56:23
EGFR in t(1;7)(p11;p11), 53:91
gene mapping in cancer, 55:139
in adipose tissue tumors, 52:262
in ANLL with t(8;20)(q13;q13), 52:1
in AT, 56:143
in brain tumors, 52:248
in breast cancer, 52:224
in breast cancer cell lines, 51:239
in CLL, 57:187
in CLL (c-*myc* and K-*ras*-2), 51:125
in Ewing sarcoma, 52:271
in germ cell tumors, 52:277–279
in giant cell tumor of bone, 56:263
in hereditary melanoma, 51:45

in Hodgkin disease, 51:103
in interphase nuclei, 51:23
in large bowel adenomas and cancer, 52:233–234, 236; 56:45
in leiomyoma, 54:223
in lung cancer, 52:228
in marrow engraftment, 55:181
in MDS, 56:1
in medulloblastoma with i(17q), 57:181
in melanoma, 52:257
in meningioma, 53:271
in neuroblastoma, 52:275
in neurofibromatosis 1, 52:250
in osteosarcoma, 57:31
in Ph+ acute leukemia, 51:259
in Ph+ ALL, 51:259
in Ph+, *bcr*+ essential thrombocythemia, 54:21
in Ph+ CML, 51:259; 54:247; 57:193
in Ph-negative CML, 52:143
in polyposis coli, 52:229
in renal cell cancer, 51:121; 52:245
in small round-cell tumors, 54:1
in stomach cancer, 52:238
in testicular tumor with osteosarcoma, 52:269
melanoma oncogene locus, 52:215
NOR studies, 52:280
Not1 on 12p, 52:280
of chromosome 5 in liver cancer, 52:240
of Ph+ leukemia, 57:143
of transformed benign human cells, 52:260
of t(8;21) in ANLL (M2), 57:103
of 3′ end of RB-1 in Ph+ ALL, 54:197
on HL-60 leukemia cells, 56:57
pS2 gene in pancreatic cancer, 52:239
pS2 gene in stomach cancer, 52:238
RFLP in marrow engraftment, 55:181
studies in osteosarcoma, 53:45
tcl-1, *tcl*-2 and *erb*-B in ATL, 51:133
TGF expression in giant cell tumor of bone, 56:263
UMPK and PGD in cancer, 56:45
YAC and chromosome 21, 57:109
YAC specific sequences in t(8;21), 57:109

Monosomy
detection with in-situ hybridization, 51:23
in Hodgkin disease, 51:105
in interphase nuclei, 51:23
in schwannomas, 57:121
−7 and others in ALL, 55:249
−7 in secondary ANLL after ALL, 55:85
−12 in ALL, 56:7
22 in leiomyoma, 53:125
−22 in schwannomas, 57:121

Mouse (Mice)
chromosome changes in transformed cells, 53:185
hepatic cell lines from SV40-T antigen gene in transgenic mice, 55:207
melanoma, 56:209
m5S cells, 53:185
nude mice, cell culture growth, 53:45
selection of tumor cells grown in nude mice, 53:45

Multiple Endocrine Neoplasia (MEN)
chromosome changes, 52:85, 222
Editorial with MEN-1, 52:131
lymphocytes and fibroblasts in, 52:85, 222
Type 1, 52:85, 52:222

Mycosis Fungoides
chromosome changes, 53:113
del(2), 53:113

Myelodysplastic Syndromes (MDS)
abnormal megakaryocytes in, 55:31
chromosome changes in, 51:4–5, 54:229; 55:31, 57; 56:203, 243
chromosome changes in RAEB, 54:229
chromosome 5 in, 56:2
chromosome 13 in, 55:149
CMMoL, 55:57
del(15)(q11q15) in CMMoL, 55:35
der(3)t(3;5) in, 54:129
fms gene, 56:4
following treatment for lung cancer, 56:115
genetic changes in, 56:1
in FA, 51:4–5
in MPD with t(3;18), 51:73
ins(8;3)(q24;q21q26) in, 55:31
i(14q) in RA, 54:133
i(21q) in, 55:101
partial trisomy 1q, 56:243
RAEB-T and ins(8;3), 55:31
random changes in marrow and their significance, 53:257
ras gene, 56:2
r(20) in RAEB, 55:238
transient with t(Y;1) in Fanconi anemia, 52:201
t(1;5)(p36;q14) in RAEB, 54:229
t(1;7)(p11;p11) in, 53:91
t(3;5)(q25;q33) in RAEB, 57:233
t(3;21) in crisis of RAEB, 57:153
1q trisomy, 56:243

Myelofibrosis
biclonal cells, 52:63
evolving to ANLL, 52:63
t(1;7)(p11;p11) in, 53:91
+8 and t(5;17)(q11;p11), 52:63

Myeloma
ABO groups in, 51:113

cytogenetics of, 55:173
t(1;7)(p11;p11) in, 53:91
#9 in, 55:173
Myeloproliferative Disorders (MPD)
dysmegakaryopoiesis, 51:73
reciprocal translocation with 3q21, 51:73
t(3;18)(q21;q21), 51:73
with MDS features, 51:73

Nasal and Nasopharyngeal cancer
chromosome changes in, 52:51
immortalized cell lines, 52:51
papillomavirus 16 DNA, 52:51
Nasopharyngeal carcinoma
loss of heterozygosity at 3p, 54:91
3p changes, 54:91
Near-haploidy
in clear cell chondrosarcoma, 52:193
Neurinoma
chromosome 22 in, 52:254
cytogenetics of, 52:254
Neuroblastoma
chromosome 1 in, 52:276; 55:231
chromosomes in, 52:276; 54:3; 55:231
del(1), del(14), HSR and dms in, 55:231
myc amplification, 52:275; 54:3, 253
N-*myc* amplification in, 54:253
prognostic aspects, 54:253
Neuroectodermal tumors
absence of t(11;22), 51:13
cases in literature, 51:20–21
cell line of tumor, 56:110
chromosome findings, 51:13
Neuroendocrine tumors
cytogenetics, 51:85
Merkel cell, 51:85
Neurofibroma
cytogenetics of, 52:254
Neurofibromatosis
cytogenetic studies in, 52:250
RFLP analysis in type 1, 52:250
Neurofibrosarcoma
cytogenetics of, 52:254
Neuroma
acoustic, 56:83
cytogenetics in acoustic, 56:83
Non-Hodgkin lymphoma (NHL); see Lymphoma
Nucleolar Organizing Regions (NOR)
in testicular tumors, 52:280

Oligodendroglioma; also see Brain and Glioma
chromosomes in, 52:253–254
Oncocytoma
renal with chromosome changes, 56:134
Oncogenes
c-*myc* and K-*ras*-2 in CLL, 51:125
c-*myc* and HL-60 leukemia cells, 56:57
erb-B in ATL, 51:133
Ha-*ras* and INS in nephroma, 52:272
in breast cancer, 52:224
in large bowel tumors, 52:233
in papillary thyroid cancer, 52:216
in small round-cell tumors, 54:1
lck in colon cancer, 52:236
melanoma locus in Xiphophorus, 52:215
met in gastric cancer cell line, 52:237
myc in neuroblastoma, 52:275
N-*myc* in neuroblastoma, 54:253
oncogene *myb* in melanoma, 52:219
oncogenes in breast cancer lines, 51:239
RB-1 in osteosarcoma of Sertoli Leydig tumor of testis, 52:269
Osteosarcoma
cell line with 13q−, 57:31
loss of heterozygosity of 13 and 17, 53:45
molecular studies in, 57:31
small cell, 54:1
suppressor genes in, 53:45
t(11;22)(q24;q12) in, 54:1
13q and 17p in, 53:45; 57:31
Ovary
benign tumors, 52:230
chromosome changes, 52:240; 55:89
granulosa cell tumor, 56:130
hereditary cancer, 53:161
immature teratoma, 56:129
mucinous cystadenoma, 52:230
numerical changes in early stages of tumors, 55:89
tumor and mosaicism in Turner syndrome, 56:114
t(1;11)(q25;q23) in cystadenoma, 52:230
+7 in early tumors, 55:89
9q12 and ERB B-2 in, 56:108
11p- in cancer, 52:243
+12 in mucinous cystadenoma, 52:230
+12 in tumors, 54:273
19p+ in seropapillary cystadenocarcinomas, 52:242
−X in adenofibroma, 52:230

Pancreas
cancer, 52:238
cytogenetic of cancer, 52:238
pS2 gene in pancreatic cancer, 52:239
Papillomavirus
in genital carcinomas, 52:230
in nasal and nasopharyngeal cells, 52:51
in pleomorphic adenomas, 52:187
integration in genital tumors, 52:230
integration sites in nasal cells, 52:51

no sequences at 3p21 of pleomorphic adenomas 52:187
type 16, 52:51, 230
Parotid gland
evolutionary characteristics, 55:19
karyotypic variability, 55:19
PCR (Polymerase Chain Reaction)
molecular markers, 52:19
residual leukemia, 52:19
Penile cancer
papillomavirus integration, 52:230
Peripheral neuroepithelioma
chromosomes in, 54:5
molecular aspects, 54:5
t(11;22)(q24;q12) in, 54:5
Peyronie Disease
chromosome changes in, 52:181
multiple clones in, 52:181
Philadelphia chromosomes (Ph)
bcr studies, 57:143
blastic phase, 51:167; 57:69
complex translocations, 55:129; 57:69, 143
derivative with 9p, 52:43
in acute leukemia, 51:259; 52:43; 57:143
in ALL, 51:259; 52:43
in ANLL, 51:227
in basophilic leukemia, 51:215
in CML, 51:167, 259; 54:247; 57:69, 143
in marrow engraftment, 55:181, 57:69
molecular differentiation of Ph's, 54:247; 57:143
positive ALL and 9p, 53:139
variant Ph in ALL, 51:260
variant Ph in CML, 57:139
variant Phs, 51:169, 260; 52:43; 54:247; 57:69, 143
Plasma cell
chromosomes in leukemia, 52:123, 135
leukemia, 52:123, 135
Pleomorphic adenomas
carcinoma in, 55:125
chromosome changes in, 52:187, 226; 55:125
clinical data, histology and chromosomes, 52:226
lacrimal gland, 55:125
no papillomavirus sequences at 3p21, 52:187
Pleomorphic Xanthoastrocytoma; see Glioma and Astrocytoma
cytogenetics of, 55:225
Polyposis coli
adenomatous, 52:229
genetic analysis, 52:229
progression, 52:229
Porokeratosis
chromosome changes in, 56:163
cultured epidermal keratinocytes, 56:163
Preleukemia
Fanconi anemia and, 51:1
in Down syndrome, 54:119
loss of all or part of #7, 54:119
Prolymphocytic leukemia
in ataxia telangiectasia, 55:1
inv(14) in, 55:1
Prostate cancer
C-bands in, 51:57
constitutive heterochromatin, 51:57
cytogenetic and immunocytochemical studies, 52:247
cytogenetics of, 55:79
in situ hybridization studies, 52:247
L-myc in, 56:103
molecular studies, 56:100, 103
polymorphisms, 51:57

Radiation
chromosome changes induced by, 56:141
FISH and radiation damage, 56:141
PCC and radiation changes, 56:141
Refractory Anemia (RA)
chromosome changes in, 51:4, 53:279; 56:243
in FA, 51:4
i(21q) in, 55:101
prognostic value of complex karyotype, 53:279
1q trisomy in, 56:243
Refractory Anemia with Excess Blasts (RAEB); see Myelodysplastic Syndromes
Renal cell carcinoma
hereditary, 51:121
in situ hybridization studies of 3p, 51:121
t(3;8) in, 51:121
+10 in, 51:137
Residual disease
detecting residual leukemia, 52:19
in acute leukemia: methodologic considerations, 52:93
Retinoblastoma
gene in interphase nuclei, 56:98
osteosarcoma in patient with, 57:31
recessive expression, 54:263
13q− in osteosarcoma of patient with, 57:31
13q14 in, 54:263
Rhabdoid tumor
cell line, 56:31
chromosome changes, 56:134, 135
extrarenal, 56:135
t(11;22)(p15.5;q11.23) in, 56:31

Rhabdomyosarcoma
cell line, 54:83
del(13q14) in alveolar, 55:257
embryonal, 54:83
karyotypes in, 52:276; 54:6, 83; 55:191, 257
loss of heterozygosity at 11p, 54:6
molecular aspects, 54:6
translocations in, 54:6, 83; 55:191
t(1;13)(p36;q14) in, 56:121
t(2;13) in, 52:276; 54:6; 55:191
t(2;13)(q35;q14) breakpoints, 56:120
variant t(2;13) in, 55:191
Ring chromosome
in a lipoma, 52:264
in astrocytoma, 52:253
in leiomyosarcoma, 54:115
in MFH, 522:258
in Ph+ CML, 57:73
in pleomorphic adenoma, 55:125
in preleukemia of DS, 54:119
in RAEB, 55:238
in uterine leiomyoma, 53:125; 55:13

Salivary glands
evolutionary chromosome changes, 55:19
karyotypic variability in parotid gland, 55:19
−22 and 10p− in adenoid cystic carcinoma, 56:139
Sarcoma
alveolar soft-part, 55:167
chondrosarcoma, 52:193, 266
clear cell, 52:101
cytogenetic heterogeneity, 52:266
endometrial, 55:163
Ewing, 52:271
fibrosarcoma, 52:37
MFH, 52:266
myxoid liposarcoma, 51:195; 52:266, 268
osteosarcoma, 53:45
rhabdomyosarcoma, 55:257
soft tissue, 52:259
synovial, 52:266
Schwannoma (neurilemoma)
chromosome changes, 57:121
classical and cellular, 57:121
in vitro growth, 57:121
Second European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumors
Abstracts, 52:215–282
Editorial comment, 52:205
Overview and Prospects, 52:207
Program, 52:203
Secondary leukemia
alkylating agents and type of, 55:119
ANLL after ALL, 55:85
characteristics, 55:119
cytostatic drugs and type of, 55:119
erythroleukemia with near-triploid karyotype, 54:11
Hodgkin disease and Ph+ CML, 55:277
karyotype, 54:11; 55:85, 199
response to therapy, 55:119
secondary Ph+ CML, 55:217, 277
−7 in, 55:85, 119
11q23 and 21q22 in, 55:119
Sézary syndrome
chromosome changes in, 53:113
del(2), 53:113
Sister chromatid exchange (SCE)
biclonal analysis, 52:71
busulfan induced in Ph+ CML, 52:71
in BL, effect of mitomycin C, 56:105
in blast crisis of CML, 52:71
in familial melanoma, 53:237, 265
in kidney cells and renal cancer, 52:244
in melanoma patients, 53:237
UV-effects in melanoma families, 53:265
Skin tumors
cytogenetics, 51:85
Merkel cell, 51:85
Small round-cell tumors
cytogenetic aspects, 54:1–2
ectomesenchymoma, 54:4
esthesioneuroblastoma, 54:3
Ewing sarcoma, 54:1
medulloblastoma, 54:3; 57:133
melanotic neuroectodermal tumor of infancy, 54:4
molecular studies in, 54:2–3
neuroblastoma, 54:3
peripheral neuroepithelioma, 54:5
rhabdomyosarcoma, 54:6
small cell osteosarcoma, 54:5–6
+8 in esthesioneuroblastoma, 57:133
Soft tissue
DNA ploidy in sarcoma, 52:259
fine needle aspiration in tumors, 56:120
karyotypes in sarcoma, 52:259
sarcomas, 52:259
Spinal tumors
cytogenetics of, 56:126
pediatric, 56:126
Squamous cell carcinoma
chromosome changes in, 52:220; 55:153
monoclonal or polyclonal in origin, 54:135
of head and neck, 52:220; 54:135
of skin, 56:138
of vagina, 55:153
of vulva, 56:132
1p22 and 11q13 in, 52:220

Stomach
cell line, 55:67
chromosome changes in, 55:67
familial cancer, 52:237
familial polyposis, 53:97
genetic and histologic studies in familial cancer, 52:237
i(8q) in cancer, 54:137
met oncogene in cancer cell line, 52:237
pS2 gene in, 52:238
+8,+8 in M4 developing after gastric cancer operation, 54:27
−Y in cancer, 52:236; 55:67
Suppressor gene(s)
in lung tumor, 52:228
in melanoma, 52:257
in meningioma, 52:250
in osteosarcoma, 53:45
Synovial sarcoma
mediastinal, 55:265
t(X;15;18)(p11.2;q15;q11.2) in, 52:266
t(X;18)(p11;q11) in, 55:265
t(X;18)(p11.2;q11.2) in, 52:266–267

T-cell
adult leukemia, 51:131
ALL with myeloid markers and t(4;11), 56:255
chromosome changes, 51:133; 55:1
leukemias in AT, 55:1
lymphoma with der(6), 54:269
Techniques; see Methods
Telomere
association in giant cell tumor of bone, 56:263; 57:161
fusion in AT, 56:143
in cancer, 54:245
Teratoma
cytogenetic analysis, 56:129; 57:59
mature and immature components in germ cell tumor, 57:59
Testes
chromosomes in tumors, 52:113, 278; 56:97; 57:59
hematological disorder after therapy for germ cell tumor, 52:281
in situ hybridization, 56:95, 97
in situ hybridization for #1 in seminal fluid, 52:271
in situ hybridization of #12, 52:279
i(12p) in tumors, 52:113, 278; 57:59
lymphocytes in familial cases, 52:281
nonseminoma germ cell tumors, 57:59
NOR in testicular tumors, 52:280
osteosarcoma in tumor, 52:269
RB-1 gene in osteosarcoma of Sertoli Leydig tumor, 52:269
Sertoli Leydig cell tumor, 52:269
suppressor genes in germ cell tumors, 52:277–278
teratoma components in germ cell tumor, 57:59
tumors, 52:113, 278
11p13 in germ cell tumors, 52:277, 279
Therapy-related leukemia, see Secondary leukemia
Thymus tumors and hyperplasia
cytogenetic findings, 52:227
Thyroid
adenomas, 52:157; 56:124, 125, 231
chromosome 10 in benign and malignant thyroid tumors, 53:15; 55:73; 57:209
chromosomes in adenomas, 52:157, 221; 55:73; 56:106, 231, 277
chromosomes in follicular adenomas, 56:124, 231, 277
chromosomes in follicular carcinoma, 54:215; 56:124
chromosomes in medullary cancer, 56:106
chromosomes 10 and 17 in adenomas, 52:157
cytogenetics of nodular hyperplasia, 53:15; 55:73
cytogenetics of papillary cancer, 52:216, 221; 56:124; 57:209
goiter, 55:73
idic(22;22)(p11;p11) in cancer, 54:215
in multinodular goiters, 52:221
LOH in, 56:124
nodular hyperplasia after irradiation for HD, 53:15
papillary carcinoma, 56:124, 125; 57:209
+7 in multinodular goiter, 55:73
13p- in follicular adenoma, 56:277
Translocations
dic(7;14)(q11p11) in neuroectodermal tumor, 51:16
in ATL, 51:131
inv(1;13)(q32p36;q14) in rhabdomyosarcoma, 55:193
"jumping" translocation in lipoma, 52:264
"jumping translocations", 51:189; 52:264
translocations involving 11q23–24 in ANLL, 55:160
translocations with 3q13.3 in M5, 51:189
(X;3;1)(q24;q25;p36) in leiomyoma, 55:13
(X;4)(q13;q35) in HD, 51:105
(X;12)(q22;p13) in mesothelioma, 55:115
(X;14)(q11;q11) in ATL, 51:133

(X;14)(q28;q11) in T-leukemia in AT, 55:1
(X;15;18)(p11.2;q15;q11.2) in synovial sarcoma, 52:266
(X;16)(q25;q24) in neuroectodermal tumor, 51:21
(X;18)(p11.2;q11.2) in synovial sarcoma, 52:266; 267
(X;18)(q12;p11.3) in ALL cell line, 53:23
(Y;1)(q12;q21) transient in FA, 52:201
(1;1)(p32;q21) in neuroblastoma, 54:1
(1;1)(p32;q23) in pancreatic cancer, 52:239
(1;1)(p36;q22) in plasma cell leukemia, 52:135
(1;2)(p13.3;q21) in leiomyoma, 53:247
(1;2)(p32;p21) in leiomyoma, 55:14
(1;2)(p36;p24) in uterine leiomyoma, 53:125
(1;2)(q21;p21) in leiomyoma, 54:223
(1;2)(q25;q33) in M2, 53:83
(1;2;3;5) in acute leukemia, 52:165
(1;3)(q21;q29) in atherosclerotic plaque, 52:262
(1;3)(q22;q27) in neuroectodermal tumor, 51:20
(1;3)(q44;p21) in breast cancer, 53:205
(1;3;8)(p22;p21;q12) in pleomorphic adenoma, 52:187
(1;4)(p31;q28) in CMMoL, 55:57
(1;4)(p36;p13) in neuroectodermal tumor, 51:20
(1;4)(p36;p13) in rhabdomyosarcoma cell line, 54:83
(1;5)(p13;q31) in esophageal cancer, 55:197
(1;5)(p34;q31) in MDS of FA, 51:5
(1;5)(p36;q35) in AML, 54:199
(1;6)(p34 or 35; p24 or 25) in CLL, 53:35
(1;6)(p36;p21) in B-CLL, 55:49
(1;6)(q12;p25) in RA of FA, 51:4
(1;6)(q21;q13) in medulloblastoma, 53:101
(1;6)(q22 or 23;p25) in AA of FA, 51:4
(1;6)(q22 or 23;pter) in M7 of FA, 51:3
(1;6)(q23;p25) in ANLL, 53:84
(1;6)(q32;p25) in M7 of FA, 51:3
(1;6)(q44;q21) in ALL, 52:109
(1;7)(p11;p11) in CMMoL, 55:57
(1;7)(p11;p11) in hematologic disorders, 53:91
(1;7)(q12;q36) in astrocytoma, 53:119
(1;7)(q21;p22) in pancreatic cancer, 52:239
(1;8)(p23;q24) in plasma cell leukemia, 52:135
(1;8)(q25;p21) in leiomyoma, 55:13
(1;9)(p12;p12) constitutional in patient with Wilms tumor, 52:272
(1;9)(q12;q12) in PV, 55:238
(1q;9q;11q) in neuroectodermal tumor, 51:20
(1;9;3;10) in hemangiopericytoma, 54:173
(1;9;22)(q32;q34;q11) in CML, 51:169
(1;10)(p32;q24) in neuroblastoma, 54:1
(1;10)(q25;p13) in leiomyoma, 55:13
(1;10;?)(q11;p15;?) in MFH, 52:266
(1;11)(p36;q13) in B-CLL, 55:49
(1;11)(p36;q23) in ANLL, 51:228
(1;11)(q21;p15) in breast cancer, 53:205
(1;11)(q25;p15) in leiomyoma, 55:13
(1;11)(q25;q23) in mucinous cystadenoma, 52:230
(1;11)(q42;q13–14) in parotid cancer, 55:19
(1;12)(p32;p11) in ALL, 55:252
(1;12)(p32;p13) in lymphoma, 53:113
(1;12)(q42;q13) in myxoid liposarcoma, 51:195
(1;12;16)(p11;q13;p11) in myxoid liposarcoma, 51:195
(1;13)(p12;q12) in MDS, 55:149
(1;13)(p32;p15) in neuroblastoma, 54:1
(1;13)(p36.2;q12) in uterine leiomyoma, 53:125
(1q13q) in AA of FA, 51:5
(1;13)(q25;q14) in hemangiopericytoma, 54:173
(1;13)(q32;q22) in rhabdomyosarcoma cell line, 54:83
(1;13;6)(q21;q22;q26) in CLL, 53:35
(1;13;14)(p11;q11;q32) in ALL, 51:229
(1;14)(p21;q11) in T-leukemia in AT, 55:1
(1;14)(p21;q11) in T-PLL in AT, 55:1
(1;14)(p36;q32) in lymphoma, 53:229
(1;14)(q11;q13) in chondrosarcoma, 52:266
(1;14)(q12;p12) in CMMoL, 55:57
(1;14)(q12 or 21;q32) in M7 of FA, 51:3
(1;14)(q32;q13) in astrocytoma, 53:119
(1;14)(q42;q11) in pre-ATL, 51:133
(1;14)(q44;q22) in lung adenocarcinoma, 52:231
(1;15)(p11;p11) in hemangiopericytoma, 54:173
(1;15)(p15;q25) in astrocytoma, 53:119
(1;15)(q11;p11) in ALL, 55:253
(1;16)(q12;q24) in alveolar soft-part sarcoma, 55:171
(1;16)(q21;q23) in ALL, 54:199
(1;16)(q23;q23) in ALL, 54:199
(1;16)(q32;q22) in M4, 51:235

(1;17)(q21;p13) in M7 of FA, 51:4
(1;18)(q21;q21) in neuroectodermal tumor, 51:21
(1;19)(p22;p13) in ovarian cancer, 52:242
(1;19)(q11;p13) in oligodendroglioma, 52:253
(1;19)(q12;q13) in leiomyoma, 55:14
(1;19)(q23;p13) in ALL, 52:109; 54:199
(1;19)(q23;p13.3) in ALL, 55:249
(1;21)(q12;q22) in myxoid liposarcoma, 51:201
(1;22)(p12–13;q13) in M7, 54:259
(2;3)(p13;q26 or 27) in Merkel cell tumor, 51:85
(2;5)(q26;q13) in chondrosarcoma, 52:266
(2;6)(p15;p12) in astrocytoma, 53:119
(2;6)(q37;p21) in leiomyoma, 55:14
(2;8)(q21;q11) in T-PLL, 55:1
(2;8)(q37;q13) in rhabdomyosarcoma, 54:1
(2;9)(p13;p13) in plasma cell leukemia, 52:123
(2;9)(q11.2;p22) in clear cell sarcoma, 52:101
(2;9)(q35;q11) in T-cell lymphoma, 54:269
(2;11)(p21;q13) in leiomyoma, 54:223
(2;11)(q11;q13) in Peyronie disease, 52:181
(2;11)(q11;p15) in leiomyoma, 55:14
(2;11)(q27;q13) in rhabdomyosarcoma, 54:1
(2;11;22;21)(q32;q24;q12;p11) in neuroectodermal tumor, 51:20
(2;12)(q36;q15) in uterine leiomyoma, 53:125
(2;13)(p21;q12) in leiomyoma, 55:14
(2;13)(q13;q22) in astrocytoma, 53:119
(2;13)(q35;q14) in rhabdomyosarcoma, 54:1
(2;13)(q37;q14) in rhabdomyosarcoma, 54:1
(2;15;21)(p14;q22.3;q12) in neuroectodermal tumor, 51:16
(2;16)(q21;q11) in blastic phase of CMMoL, 55:60
(2;19)(p11;q13.3) in leiomyoma, 53:247
(2;22)(p25;q11) in ALL, 54:199
(2;22)(p25;q11) in Ph+ ALL, 51:260
(3;3)(p24;q13) in leiomyoma, 55:14
(3;4)(p14;p16) in hemangiopericytoma, 54:173
(3;4)(q13;p16) in plasma cell leukemia, 52:135
(3;4;8)(p26;p13 or 14;q12) in pleomorphic adenoma, 52:187
(3;6)(q21;p21) in dysmegakaryopoiesis (ANLL), 51:77
(3;8)(p21;q12) in pleomorphic adenoma, 52:187
(3;8)(q11;p22) in blastic phase of CMMoL, 55:60
(3;8)(q21;q24) in astrocytoma, 53:119
(3;9)(q21;q34) in dysmegakaryopoiesis (BC-CML), 51:77
(3;10)(p21;q22) in hyperplastic thyroid, 53:15
(3;11)(q21;p15) in CMMoL, 55:57
(3;11)(q24;q24) in astrocytoma, 52:253
(3;12)(q12;q22) in CMMoL, 55:57
(3;12)(q21;p13) in dysmegakaryopoiesis (MDS), 51:77
(3;12)(q28;q13) in ALL, 55:261
(3;12)(q28;q14) in lipoma, 52:262
(3;13)(p12 or 13;q12) in CLL, 53:35
(3;14)(q26;q11) in megakaryoblastic phase of Ph+ CML, 55:133
(3;15)(p23;q15) in myxoid liposarcoma, 51:195
(3;16)(q21;q22) in dysmegakaryopoiesis (MDS), 51:77
(3;inv(16)(q26;q22q26) in M4, 55:269
(3;17)(p11;q25) in M4, 51:79
(3;17)(q25;q25) in ANLL, 52:1
(3;18)(q21;q21) in MPD, 51:73
(3;18)(q21;q21) in MPD-MDS, 51:77
(3;21)(p21;q22) in neuroectodermal tumor, 51:21
(3;21)(q14;q11) in Peyronie disease, 52:181
(3;22)(q11;p11) in Peyronie disease, 52:181
(3;22)(q21;q13) in dysmegakaryopoiesis (AMMoL), 51:77
(4;5)(q31;q11) in HD, 51:105
(4;6)(p11;p11) in astrocytoma, 53:119
(4;6)(p14;q11) in M2, 53:83
(4;6)(p15;q24) in leiomyoma, 55:13
(4;8)(p14;q12) in pleomorphic adenoma, 52:187
(4;8)(q12;q24.1) in B-CLL, 55:49
(4;11)(q21;q23) in ALL, 55:253
(4;11)(q21;q23) in M4, 51:79
(4;13)(q13;q34) in rhabdomyosarcoma, 54:1
(4;14)(p14;p11) in basal cell carcinoma, 52:220
(4;14)(q21;q32) in lymphoma, 53:113
(4;16)(q21;q23) in astrocytoma, 52:253
(4;22)(p16;q11) in meningioma, 52:250
(4;22)(q13;q13) in neuroectodermal tumor, 51:20

(5;6;10)(p11;p11q11;q11) in Peyronie disease, 52:181
(5;7)(p15;q22) in M4 of FA, 51:3
(5;7)(q12–13;q36) in ALL-L1, 52:173
(5;8)(p15;q13) in parotid cancer, 55:19
(5;8)(q14;q24) in plasma cell leukemia, 52:135
(5;9)(q13;p13),t(9;22)(q34;q11) in ALL, 52:43
(5;11)(p15;p15.3) in astrocytoma, 53:119
(5;11)(q21;p15) in stomach cancer, 55:67
(5;12)(q31;p12) in atypical CMMoL with eosinophilia, 51:277
(5;13)(p13;q22) in leiomyoma, 55:13
(5;14)(q13;q32) in leiomyoma, 53:247
(5;15)(p15.3;q13) in clear cell sarcoma, 52:105
(5;17) in various hematologic conditions, 52:67
(5;17)(q11;p11) in myelofibrosis, 52:63
(5;17)(q33;q25) in hyperplastic thyroid, 53:15
(5q18q) in M4 in FA, 51:3
(5;20)(p15;q11) in chondrosarcoma, 52:266
(6;7)(p21;p13) in T-cell lymphoma, 54:269
(6;7)(q13;p13) in T-cell lymphoma, 54:269
(6;8)(q15;q24) in leiomyoma, 55:14
(6;9)(p23;q31) in Ph+ CML, 55:238
(6;9;22)(q23;q34;q11) in BP of CML, 51:170
(6;10)(q12;q25) in CLL, 53:35
(6;12)(p22;q13) in leiomyoma, 55:13
(6;12)(q21;p13) in ALL, 55:252
(6;13)(p25;q14) in CLL, 53:35
(6;13)(q11;p12) in MDS, 55:149
(6;14)(p12;q11) in CLL, 53:35
(6;14)(p21.3;q24) in uterine leiomyoma, 53:125
(6;20)(p21;q11) in CLL, 53:35
(6;20)(p21;q13) in endometrial polyp, 52:1
(6;22)(p22;q12) in clear cell hidradenoma, 52:226
(7;7)(q22;q11) in HD, 51:105
(7;8)(p12;p23) in uterine leiomyoma, 53:125
(7;8)(p14;p12) in leiomyoma, 55:14
(7;8)(q32;q22) in Ph+ CML, 55:238
(7;9;22)(q22;q34;q11) in CML, 51:169
(7;11)(p11;p15) in CML, 54:199
(7;12)(q31.2;q21.2) in leiomyoma, 55:14
(7;12;17)(q22;q24;q21) in HD, 51:105
(7;13)(q11.1;p13) in endometrial sarcoma, 55:163
(7;14)(p11–12;q11) in ATL, 51:133
(7;14)(p15;q11) in ALL, 52:109
(7;14)(q32;q11) in pre-ATL, 51:133
(7;16)(q21;q24) in neuroectodermal tumor, 51:20
(7;16)(q22;q22) in breast cancer, 53:205
(7;17)(p21;q12) in endometrial sarcoma, 55:163
(7;17)(q32;p13) in chondrosarcoma, 52:266
(8;8)(p12;q11) in T-leukemia in AT, 55:1
(8;12;16)(q21;q13;p11) in liposarcoma, 52:269
(8;14)(p21;q11) in plasma cell leukemia, 52:135
(8;14)(q24;q32) in ALL, 52:109
(8;14)(q24;q32) in ALL-L3, 52:173
(8;16)(q13;q24) in lacrimal gland tumor, 55:125
(8;20)(q13;q13) in ANLL, 52:1
(8;21)(p12;q11) in T-PLL, 55:1
(8;21)(q22;q22) in CMMoL, 51:139
(8;21)(q22;q22) in Ph+ leukemia, 51:215
(8;22)(q24;q11) in T-PLL in AT, 55:1
(9;10;11)(q32;q22;q13.5) in leiomyoma, 53:247
(9;11;16)(p22;q23;p13) in M5, 54:163
(9;12;22)(q34;q22;q11) in BP of CML, 51:171
(9;13)(q11;q34) in plasma cell leukemia, 52:135
(9;14)(q12 or 13;p11) in basal cell carcinoma, 54:33
(9;16)(p12;p11) in myeloma, 55:175
(9;17)(q12;p13) in ALL, 55:253
(9;17;15)(q22;q11.2;q22) in chondrosarcoma, 52:267
(9;18)(q22;q23) in astrocytoma, 53:119
(9;22)(q34;q11) in ALL, 52:109; 55:253
(9;22)(q34;q11) in basophilic leukemia, 51:215
(9;22)(q34;q11),der(19)t(9;19)(p13;p13) in ALL, 52:43
(9;22)(q34;q12) in CML, 51:169
(9;22)(q34;q13) in CML, 51:169; 54:199
(10;11;22)(p11;q24;q12) in Ewing sarcoma, 56:96
(10;14)(p13;q24) in leiomyoma, 54:223
(10;14;14)(p11;q11q32;q11) in T-PLL, 55:1
(10;16)(q11;p11) in rhabdomyosarcoma, 55:258
(10;16)(q22;p11) in myxoid liposarcoma, 51:195
(10;17)(p13;q25) in astrocytoma, 53:119
(10;22)(q26;q11) in CML, 51:169
(11;8)(p15;q13) in parotid cancer, 55:20
(11;12)(p13;q13) in myxoid liposarcoma, 51:201
(11;12)(p15;q13) in myxoid liposarcoma, 51:201

(11;12)(q12;q23) in bladder cells, 52:246
(11;12)(q13;q24) in ALL, 51:229
(11;14)(p15;q24) in lymphoma, 53:113
(11;14)(q13;q32) in B-CLL, 55:49
(11;14)(q13;q32) in CLL, 53:35
(11;14;14)(p11;q11q32;q11) in T-PLL, 55:1
(11;17)(q13;q21) in myxoid liposarcoma, 51:195
(11;19)(q11;p13) in pancreatic cancer, 52:243
(11;19)(q23;p13) in AML-M1, 54:199
(11;19)(q23.3;p13.3) in ALL, 55:253
(11;22)(q21;q12) in esthesioneuroblastoma, 54:1
(11;22)(q24;q12) in esthesioneuroblastoma, 54:1
(11;22)(q24,q12) in Ewing sarcoma, 52:273
(11;22)(q24;q12) in Ewing sarcoma and peripheral neuroepithelioma, 54:1
(11;22)(q24;q12) in Ewing's type translocation in ANLL, 55:157
(11;22)(q24;q12) in neuroectodermal tumors, 51:13
(12;13;15)(p13;q31;q21) in blastic phase of CMMoL, 55:60
(12;14)(p13;q22) in neuroectodermal tumor, 51:21
(12;14)(q14–15;q23–24) in leiomyoma, 52:261, 263; 55:11
(12;14;18)(q14–15;q23–24;q12.3) in leiomyoma, 53:247
(12;15)(p12;q13) in ALL, 55:252
(12;15)(q15;q24) in leiomyoma, 54:223
(12;16)(q13;p11) in liposarcoma, 52:262, 268, 269
(12;16)(q13;p11) in myxoid liposarcoma, 51:195
(12;16)(q13;q13) in ALL, 52:109
(12;16)(q15;q24) in leiomyoma, 55:14
(12;16;16)(p11q21;p11;q12) in myxoid liposarcoma, 51:195
(12;18)(q11;q23) in chondrosarcoma, 52:266
(12;19)(q13;p13 or q13) in myxoid liposarcoma, 51:195
(12;19)(q13;q13.3) in hemangiopericytoma, 54:173
(12;21;?)(p11;p11q22;?) in MFH, 52:266
(12;22)(p13;q11) in CML, 51:169
(12;22)(p13;q12) in M4, 51:255
(12;22)(q13;q13) in clear cell sarcoma, 52:101
(13;14)(p11;q11) in leiomyoma, 53:247
(13;17)(q13;p11) in T-cell lymphoma, 54:269
(13;18)(p?;q11) in MFH, 52:266
(14;14)(q11;q32) in ALL, 55:249
(14;14)(q11;q32) in T-leukemia in AT, 55:1
(14;15)(p11;q11) in breast cancer, 53:205
(14;15)(q11;p11) in HTLV-1 carriers, 51:133
(14;15)(q11;q15) in pre-ATL, 51:133
(14;18)(q12;q22) in Peyronie disease, 52:181
(14;18)(q32;q21) in lymphoma, 53:229
(14;19)(q32;q13.1) in biphenotypic acute leukemia, 53:67
(14;20;?)(q11;p13;?) in MFH, 52:266
(14;22)(q11;p11) in HTLV-1 carriers, 51:133
(15;16)(q15;p13) in biphenotypic acute leukemia, 53:67
(15;17)(q22;q12–21) in BP of CML, 51:170
(15;17)(q24;q12) in APL-M3, 54:265
(15;19)(q15;q13 or p13) in MFH, 52:266
(15;20)(q11;q13) in pleomorphic xanthoastrocytoma, 55:225
(15;22)(p11;q11) in Ph+ CML, 54:247
(16;17)(p13.3;q21.3) in HD, 51:105
(16;17)(q22;q11) in breast cancer, 53:205
(16;21)(p11;q11) in alveolar soft-part sarcoma, 55:171
(16;21)(p11;q22) in M5, 54:61
(16;21)(p11.2;q22) in ANLL, 53:83
(17;19)(q12;p13) in liposarcoma, 52:269
(21;21)(p11;q11) in astrocytoma, 52:253
(21;21)(q22.1;q22.5) in M5, 54:163
(22;22)(p11;p11) in thyroid cancer, 54:215
Triplications
in ANLL of FA, 51:1
Trisomy
in B-CLL, 55:49
in goiter, 55:73
in schwannomas, 57:121
1q (partial) in MDS, 56:243
+4 and +9 in M2, 55:273
+5 and megakaryocytosis, 51:273
+5 in M5, 54:167
+7 in early gynecologic tumors, 55:89
+7 in gonadal tumor, 57:219
+7 in nodular goiter, 55:73
+8 and others in ALL, 55:249
+8 as a separate clone in myelofibrosis, 52:63
+8 as secondary change in myxoid sarcoma, 51:195
+8 in AMoL, 51:189
+8 in CML, 51:167
+8 in CMMoL, 55:57
+8 in esthesioneuroblastoma, 57:133
+10 in renal cell carcinoma, 51:137
+11 and +20 in fibrosarcoma, 52:37
+12 in B-CLL, 55:49

+12 in benign ovarian tumors, 52:230
+12 in female genitourinary tumors, 54:273
+12 in leiomyoma, 52:261
+13 in acute leukemia, 56:39; 57:79
+13 in myeloid conditions in males, 57:79
13q in ANLL, 55:107
+19 in CML, 51:167
+22 in M2, 56:281
+X, +7 and +10 in normal kidney cells in cancer, 52:244
Tuberous sclerosis
angiofibromas from, 52:265
cytogenetics of angiofibromas, 52:265
Tumors
bladder, 52:113
breast, 52:113
cervix, 52:113
chromosome changes and their meaning, 52:248
cytogenetic heterogeneity of "dominant" clones, 54:153
kidney, 51:121, 137
large bowel, 52:113
liposarcoma, 51:195
liver, 51:281
meningioma, 51:35
neuroectodermal, 51:13
prostate, 51:57
Registry, 52:258
testes, 52:113
thyroid, 52:157
Turcot syndrome
benign and malignant tumors, 56:140
chromosomes in tumors of, 56:140

Uterus; also see Endometrium
clonal changes in sarcoma, 55:163
karyotypes of leiomyomas, 52:261; 53:199, 247
leiomyomas, 52:261; 53:247
translocations in sarcoma, 55:163
t(6;20) in polyp, 51:279
+12 in tumors, 54:273

Vagina
squamous cell carcinoma of, 55:153
3p−,i(5p),i(8q),11q−,15p+ and 22p+ in, 55:153
Virus
E6/E7 genes of papilloma virus, 576:105
tumor suppression and;, 56:105
viral transformation and 9q11–9q34 and 8q22–8qter, 56:132
Von Hippel-Lindau syndrome
3p14 fragile site, 56:157

Vulva
chromosome changes, 56:132
squamous cell carcinoma, 56:132

Wilms' tumor
absence of specific centromeric DNA of chromosome 11 in family, 56:113
chromosomes in, 52:272
electron microscopy, 54:267
genes involved in, 52:270
t(1;9)(p12;p12) constitutional in patient with, 52:272
uniparental −11 in refractory, 56:133
1q in, 52:270
11p13 and 11p15 in, 52:270
16q in, 52:270

X chromosome
abnormalities in marrow of donors, 55:39
fragile sites and active genes, 54:71
fragile sites at Xp22.31 and Xq22.1, 54:71
+X in ALL, 52:109
+X in normal kidney cells in cancer, 52:244
−X in adenofibroma of ovary, 52:230
−X in gliomas, 52:249
−X in schwannomas, 57:124
Xp11.2 in renal cancer, 57:11
Xeroderma Pigmentosum
cancer predisposition, 57:1
chromosome changes in fibroblasts, 51:89
fibroblasts, 51:89
group C fibroblasts, 57:1
heterozygotes and homozygotes, 51:89
radiation-induced chromatid aberrations, 57:1
X-linked lymphoproliferative disease (XLP)
detection of families, 51:143
diagnosis, 51:143
infectious mononucleosis, 51:143

Y chromosome
in marrow engraftment, 55:181
in prostate cancer, 55:79
inv dup(Y)(q11→12) in T-lymphoma, 54:269
loss in marrow donors, 55:47
−Y in acoustic neuroma, 56:83
−Y in ALL, 56:7
−Y in CMMoL, 52:139; 55:57
−Y in gliomas, 52:249
−Y in normal kidney cells in cancer, 52:244
−Y in Peyronie disease, 52:181
−Y in stomach cancer, 52:236